_MEMBER_data_imp_1 - 1.8-2.2,_MEMBER_data_imp_1 - 4.5-5.5,_MEMBER_data_imp_1 - 9.0-11.0,_LogP_data_imp_1 - 1.8-2.2,_LogP_data_imp_1 - 4.5-5.5,_LogP_data_imp_1 - 9.0-11.0,GO,Description,_PATTERN_,_RANK_,GiniIndex
1,1,1,-5.5,-3.6,-3.3,GO:0007519,skeletal muscle tissue development,M111,3,0
1,1,1,-4.7,-2.6,-2.9,R-HSA-166520,Signaling by NTRKs,M111,3,0
1,1,1,-3.2,-3,-2.5,GO:0001764,neuron migration,M111,3,0
1,1,1,-8.8,-7.5,-4.6,GO:0048562,embryonic organ morphogenesis,M111,3,0
1,1,1,-12,-5.3,-4.8,GO:0140747,regulation of ncRNA transcription,M111,3,0
1,1,1,-2.7,-3.1,-2.9,WP3929,Chemokine signaling pathway,M111,3,0
1,1,1,-6.9,-6.6,-5,GO:0050678,regulation of epithelial cell proliferation,M111,3,0
1,1,1,-4.9,-3.5,-2.1,M26,PID NFKAPPAB ATYPICAL PATHWAY,M111,3,0
1,1,1,-2.2,-2.6,-2.8,GO:0032943,mononuclear cell proliferation,M111,3,0
1,1,1,-3.8,-4,-3.8,hsa05221,Acute myeloid leukemia,M111,3,0
1,1,1,-8.8,-9.2,-7.8,M167,PID AP1 PATHWAY,M111,3,0
1,1,1,-6.3,-4,-2.6,GO:0032870,cellular response to hormone stimulus,M111,3,0
1,1,1,-8.8,-5.5,-6.7,GO:0051216,cartilage development,M111,3,0
1,1,1,-5.1,-3.2,-3.3,GO:0002262,myeloid cell homeostasis,M111,3,0
1,1,1,-5.4,-4.3,-4.7,GO:0042063,gliogenesis,M111,3,0
1,1,1,-2.3,-4.9,-2.1,R-HSA-8951671,RUNX3 regulates YAP1-mediated transcription,M111,3,0
1,1,1,-8,-4.7,-3.4,hsa05166,Human T-cell leukemia virus 1 infection,M111,3,0
1,1,1,-3.6,-2.1,-2.1,WP3646,Hepatitis C and hepatocellular carcinoma,M111,3,0
1,1,1,-7.4,-4.3,-2.5,GO:0035914,skeletal muscle cell differentiation,M111,3,0
1,1,1,-4.5,-2.6,-4.6,R-HSA-9658195,Leishmania infection,M111,3,0
1,1,1,-8.3,-9.7,-7.2,GO:0070848,response to growth factor,M111,3,0
1,1,1,-8.8,-4.8,-2.7,GO:0003002,regionalization,M111,3,0
1,1,1,-2.6,-2.5,-2.8,WP363,Wnt signaling pathway,M111,3,0
1,1,1,-9.1,-5.3,-5.3,WP2849,Hematopoietic stem cell differentiation,M111,3,0
1,1,1,-2.2,-3.5,-2.5,WP1528,Physiological and pathological hypertrophy of the heart,M111,3,0
1,1,1,-8.2,-5.9,-4.8,GO:2000630,positive regulation of miRNA metabolic process,M111,3,0
1,1,1,-2.5,-5.3,-2,GO:0030509,BMP signaling pathway,M111,3,0
1,1,1,-5.2,-5.1,-2.9,GO:0022407,regulation of cell-cell adhesion,M111,3,0
1,1,1,-3.2,-2.1,-4.3,GO:0021781,glial cell fate commitment,M111,3,0
1,1,1,-3.6,-3.6,-5.1,GO:0045580,regulation of T cell differentiation,M111,3,0
1,1,1,-4,-5.5,-4.4,GO:0050863,regulation of T cell activation,M111,3,0
1,1,1,-4.4,-6.1,-2.6,GO:0042471,ear morphogenesis,M111,3,0
1,1,1,-6.5,-2.8,-2.4,GO:0002065,columnar/cuboidal epithelial cell differentiation,M111,3,0
1,1,1,-7.2,-6.7,-3.2,R-HSA-9006934,Signaling by Receptor Tyrosine Kinases,M111,3,0
1,1,1,-5.1,-3.8,-5,hsa05169,Epstein-Barr virus infection,M111,3,0
1,1,1,-7,-2.4,-2.4,GO:0002066,columnar/cuboidal epithelial cell development,M111,3,0
1,1,1,-4.3,-3.2,-3,GO:0140467,integrated stress response signaling,M111,3,0
1,1,1,-3.8,-3.8,-3.7,GO:0002683,negative regulation of immune system process,M111,3,0
1,1,1,-9.1,-5.4,-3.4,GO:0007389,pattern specification process,M111,3,0
1,1,1,-5.4,-4,-3.1,GO:0050769,positive regulation of neurogenesis,M111,3,0
1,1,1,-3.8,-4.2,-4.8,GO:0022409,positive regulation of cell-cell adhesion,M111,3,0
1,1,1,-2.1,-2.8,-3.5,CORUM:2695,ETS2-FOS-JUN complex,M111,3,0
1,1,1,-8.6,-3.7,-4.8,WP236,Adipogenesis,M111,3,0
1,1,1,-5.3,-2.1,-3.4,R-HSA-187037,Signaling by NTRK1 (TRKA),M111,3,0
1,1,1,-6.5,-4.4,-3.2,GO:0034101,erythrocyte homeostasis,M111,3,0
1,1,1,-2.1,-2.8,-2.2,GO:0032675,regulation of interleukin-6 production,M111,3,0
1,1,1,-3,-3.4,-3.1,WP4844,Influence of laminopathies on Wnt signaling,M111,3,0
1,1,1,-8.4,-3.1,-3.7,GO:0008285,negative regulation of cell population proliferation,M111,3,0
1,1,1,-3,-3.7,-3.2,GO:0030183,B cell differentiation,M111,3,0
1,1,1,-6.1,-4.3,-4.4,GO:0072089,stem cell proliferation,M111,3,0
1,1,1,-4.1,-2.7,-3.3,GO:0002252,immune effector process,M111,3,0
1,1,1,-7.9,-6,-3.4,GO:0030855,epithelial cell differentiation,M111,3,0
1,1,1,-2.1,-3.1,-4.4,GO:0050851,antigen receptor-mediated signaling pathway,M111,3,0
1,1,1,-8.7,-3.3,-2.4,GO:0009725,response to hormone,M111,3,0
1,1,1,-4.1,-4.7,-2.7,GO:0071417,cellular response to organonitrogen compound,M111,3,0
1,1,1,-12,-2.5,-4,GO:0060021,roof of mouth development,M111,3,0
1,1,1,-7.6,-5.3,-5.5,GO:0071695,anatomical structure maturation,M111,3,0
1,1,1,-6.7,-5.3,-3.3,R-HSA-6785807,Interleukin-4 and Interleukin-13 signaling,M111,3,0
1,1,1,-6.4,-2.5,-4.7,GO:0021543,pallium development,M111,3,0
1,1,1,-8.3,-3.8,-3.7,GO:0072091,regulation of stem cell proliferation,M111,3,0
1,1,1,-4.2,-2.6,-2.4,hsa04928,"Parathyroid hormone synthesis, secretion and action",M111,3,0
1,1,1,-6.2,-5.4,-6.5,GO:0002573,myeloid leukocyte differentiation,M111,3,0
1,1,1,-2.6,-2.3,-2.1,R-HSA-8943724,Regulation of PTEN gene transcription,M111,3,0
1,1,1,-4.6,-2.2,-4.1,GO:0050728,negative regulation of inflammatory response,M111,3,0
1,1,1,-3.2,-3,-2.2,M63,PID AVB3 OPN PATHWAY,M111,3,0
1,1,1,-4.3,-5.5,-3.4,hsa05321,Inflammatory bowel disease,M111,3,0
1,1,1,-2.4,-4.1,-3.6,M122,PID IL2 1PATHWAY,M111,3,0
1,1,1,-3.8,-3.4,-2.5,GO:0048545,response to steroid hormone,M111,3,0
1,1,1,-6.4,-4.2,-2.1,GO:0048844,artery morphogenesis,M111,3,0
1,1,1,-3.8,-2.4,-3.4,GO:0048483,autonomic nervous system development,M111,3,0
1,1,1,-3.7,-2.8,-5.6,GO:1903708,positive regulation of hemopoiesis,M111,3,0
1,1,1,-3.6,-3.8,-3.4,GO:0048663,neuron fate commitment,M111,3,0
1,1,1,-6.1,-2.5,-6.5,GO:0045637,regulation of myeloid cell differentiation,M111,3,0
1,1,1,-3.7,-3.8,-2.7,R-HSA-5663202,Diseases of signal transduction by growth factor receptors and second messengers,M111,3,0
1,1,1,-3.6,-2.2,-3.4,WP2526,PDGF pathway,M111,3,0
1,1,1,-3.9,-5.6,-2.7,GO:0001892,embryonic placenta development,M111,3,0
1,1,1,-4.4,-4.9,-2.1,GO:0051090,regulation of DNA-binding transcription factor activity,M111,3,0
1,1,1,-2.4,-2.2,-2.5,WP4258,lncRNA in canonical Wnt signaling and colorectal cancer,M111,3,0
1,1,1,-5,-5.1,-4.3,M183,PID IL6 7 PATHWAY,M111,3,0
1,1,1,-8.5,-6.2,-8.6,GO:0010720,positive regulation of cell development,M111,3,0
1,1,1,-5.4,-4.2,-6.4,GO:0050865,regulation of cell activation,M111,3,0
1,1,1,-7.5,-6.2,-6.4,GO:0021700,developmental maturation,M111,3,0
1,1,1,-3.7,-2.8,-5.6,GO:1902107,positive regulation of leukocyte differentiation,M111,3,0
1,1,1,-8.9,-7.5,-8.2,GO:0030098,lymphocyte differentiation,M111,3,0
1,1,1,-2.1,-2.8,-2.2,GO:0045058,T cell selection,M111,3,0
1,1,1,-2.3,-3.5,-3.2,R-HSA-4411364,Binding of TCF/LEF:CTNNB1 to target gene promoters,M111,3,0
1,1,1,-3.5,-2.2,-3.3,GO:0001649,osteoblast differentiation,M111,3,0
1,1,1,-4,-2.1,-3.5,hsa05215,Prostate cancer,M111,3,0
1,1,1,-11,-5.5,-4.6,GO:2000628,regulation of miRNA metabolic process,M111,3,0
1,1,1,-2.6,-4.2,-3.7,GO:0021954,central nervous system neuron development,M111,3,0
1,1,1,-5.8,-5.1,-3.9,GO:1903037,regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-2.2,-2.6,-2.8,GO:0046651,lymphocyte proliferation,M111,3,0
1,1,1,-5.3,-5.4,-2.9,GO:0043583,ear development,M111,3,0
1,1,1,-2.2,-2.4,-3.4,hsa05417,Lipid and atherosclerosis,M111,3,0
1,1,1,-11,-8,-10,GO:0030099,myeloid cell differentiation,M111,3,0
1,1,1,-6.6,-4.9,-3.5,GO:0030218,erythrocyte differentiation,M111,3,0
1,1,1,-3.6,-3,-5,GO:0019221,cytokine-mediated signaling pathway,M111,3,0
1,1,1,-10,-7.6,-4.3,GO:0007423,sensory organ development,M111,3,0
1,1,1,-7.4,-9,-5.9,GO:0071363,cellular response to growth factor stimulus,M111,3,0
1,1,1,-11,-8,-6,WP4149,White fat cell differentiation,M111,3,0
1,1,1,-11,-4.5,-4,GO:0060322,head development,M111,3,0
1,1,1,-4.8,-2,-4,GO:0031348,negative regulation of defense response,M111,3,0
1,1,1,-4.8,-4.5,-3.3,GO:0141091,transforming growth factor beta receptor superfamily signaling pathway,M111,3,0
1,1,1,-4.3,-3.5,-4.5,GO:0046631,alpha-beta T cell activation,M111,3,0
1,1,1,-6.5,-4.1,-2.3,GO:0001654,eye development,M111,3,0
1,1,1,-9.9,-5.4,-3.9,GO:0007420,brain development,M111,3,0
1,1,1,-4,-3,-2.1,GO:0007169,transmembrane receptor protein tyrosine kinase signaling pathway,M111,3,0
1,1,1,-8,-6,-8.9,GO:0042110,T cell activation,M111,3,0
1,1,1,-5.8,-3,-4.4,GO:0060173,limb development,M111,3,0
1,1,1,-11,-8.9,-7.7,GO:0008283,cell population proliferation,M111,3,0
1,1,1,-7.7,-5.7,-6.5,GO:0030217,T cell differentiation,M111,3,0
1,1,1,-2.1,-2.8,-3.5,CORUM:2693,NFAT-JUN-FOS DNA-protein complex,M111,3,0
1,1,1,-14,-9.1,-4.5,GO:0009792,embryo development ending in birth or egg hatching,M111,3,0
1,1,1,-4.8,-2.6,-5.5,GO:0050867,positive regulation of cell activation,M111,3,0
1,1,1,-3.1,-3.2,-2.1,R-HSA-8878166,Transcriptional regulation by RUNX2,M111,3,0
1,1,1,-4,-3.2,-5.6,GO:0050778,positive regulation of immune response,M111,3,0
1,1,1,-5.1,-4.3,-4.3,GO:0010001,glial cell differentiation,M111,3,0
1,1,1,-2.4,-5.7,-3,R-HSA-8878159,Transcriptional regulation by RUNX3,M111,3,0
1,1,1,-4,-2.1,-3.5,GO:0002460,adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M111,3,0
1,1,1,-2.7,-2.5,-3,GO:2000177,regulation of neural precursor cell proliferation,M111,3,0
1,1,1,-10,-5.1,-3.2,GO:0030900,forebrain development,M111,3,0
1,1,1,-4.2,-3.4,-4.7,GO:0006954,inflammatory response,M111,3,0
1,1,1,-9,-4,-2.6,GO:0001568,blood vessel development,M111,3,0
1,1,1,-6.2,-2,-4.5,GO:0048704,embryonic skeletal system morphogenesis,M111,3,0
1,1,1,-3.9,-3.2,-3.2,R-HSA-2559583,Cellular Senescence,M111,3,0
1,1,1,-4,-3.4,-2.1,GO:0051345,positive regulation of hydrolase activity,M111,3,0
1,1,1,-6.5,-4.1,-3.5,GO:0007517,muscle organ development,M111,3,0
1,1,1,-3.1,-2.1,-3,GO:0070665,positive regulation of leukocyte proliferation,M111,3,0
1,1,1,-3.1,-3.2,-3.7,GO:0043370,"regulation of CD4-positive, alpha-beta T cell differentiation",M111,3,0
1,1,1,-8.3,-8,-3.6,hsa04659,Th17 cell differentiation,M111,3,0
1,1,1,-2.7,-2.3,-5.9,GO:0030851,granulocyte differentiation,M111,3,0
1,1,1,-4.7,-3.6,-6.1,GO:0051249,regulation of lymphocyte activation,M111,3,0
1,1,1,-4.3,-3,-2.5,GO:2000736,regulation of stem cell differentiation,M111,3,0
1,1,1,-8.3,-3.7,-2.4,GO:0001944,vasculature development,M111,3,0
1,1,1,-4.2,-3.4,-3.5,GO:0050727,regulation of inflammatory response,M111,3,0
1,1,1,-8.8,-6,-5.3,GO:1902895,positive regulation of miRNA transcription,M111,3,0
1,1,1,-3,-3.7,-4.3,GO:0050870,positive regulation of T cell activation,M111,3,0
1,1,1,-2.4,-2.4,-2.4,GO:0045622,regulation of T-helper cell differentiation,M111,3,0
1,1,1,-7.2,-4.9,-5.3,R-HSA-449147,Signaling by Interleukins,M111,3,0
1,1,1,-3.6,-3.8,-3.7,WP5293,Acute myeloid leukemia,M111,3,0
1,1,1,-2.3,-2.5,-3.4,GO:0002274,myeloid leukocyte activation,M111,3,0
1,1,1,-8.8,-7.2,-3.6,GO:0001701,in utero embryonic development,M111,3,0
1,1,1,-9.9,-7.9,-10,GO:1903131,mononuclear cell differentiation,M111,3,0
1,1,1,-3.4,-3.1,-4.9,GO:1902075,cellular response to salt,M111,3,0
1,1,1,-6,-2.7,-3,WP4211,Transcriptional cascade regulating adipogenesis,M111,3,0
1,1,1,-4.3,-4,-5.2,GO:1903039,positive regulation of leukocyte cell-cell adhesion,M111,3,0
1,1,1,-4.7,-2.7,-2.6,WP2355,Corticotropin releasing hormone signaling pathway,M111,3,0
1,1,1,-6.5,-2.6,-3.4,GO:0048872,homeostasis of number of cells,M111,3,0
1,1,1,-14,-13,-8.1,GO:0048568,embryonic organ development,M111,3,0
1,1,1,-8.3,-6.4,-3,WP2840,Hair follicle development cytodifferentiation part 3 of 3,M111,3,0
1,1,1,-2.8,-2.8,-2.7,hsa05170,Human immunodeficiency virus 1 infection,M111,3,0
1,1,1,-2.6,-3.1,-2.6,GO:0070661,leukocyte proliferation,M111,3,0
1,1,1,-4.5,-3.8,-2.5,GO:0010464,regulation of mesenchymal cell proliferation,M111,3,0
1,1,1,-6,-4,-5.3,GO:0035107,appendage morphogenesis,M111,3,0
1,1,1,-3.2,-3.9,-3.2,R-HSA-2871796,FCERI mediated MAPK activation,M111,3,0
1,1,1,-2.2,-3.2,-2.2,GO:0008593,regulation of Notch signaling pathway,M111,3,0
1,1,1,-8.7,-7.7,-13,GO:0001775,cell activation,M111,3,0
1,1,1,-6.6,-5.3,-3.9,M60,PID NFAT TFPATHWAY,M111,3,0
1,1,1,-6.9,-4.4,-2.1,GO:0043010,camera-type eye development,M111,3,0
1,1,1,-3.2,-2.1,-2.2,GO:0021783,preganglionic parasympathetic fiber development,M111,3,0
1,1,1,-2.2,-2.5,-2.5,GO:0048821,erythrocyte development,M111,3,0
1,1,1,-7.3,-4.2,-2.5,GO:0150063,visual system development,M111,3,0
1,1,1,-6,-5,-3.5,GO:0048839,inner ear development,M111,3,0
1,1,1,-4.7,-4.1,-2.4,WP5130,Th17 cell differentiation pathway,M111,3,0
1,1,1,-2.6,-2.8,-2.9,GO:0061515,myeloid cell development,M111,3,0
1,1,1,-4.5,-3.6,-2.9,R-HSA-9006925,Intracellular signaling by second messengers,M111,3,0
1,1,1,-3.8,-2.7,-5.8,GO:0051251,positive regulation of lymphocyte activation,M111,3,0
1,1,1,-4.3,-3.8,-3,GO:0046632,alpha-beta T cell differentiation,M111,3,0
1,1,1,-6.1,-2.2,-3.2,M2,PID SMAD2 3NUCLEAR PATHWAY,M111,3,0
1,1,1,-4,-3,-3,GO:0002263,cell activation involved in immune response,M111,3,0
1,1,1,-3.1,-3.8,-2.4,GO:0050679,positive regulation of epithelial cell proliferation,M111,3,0
1,1,1,-5.7,-3.2,-2.8,WP366,TGF beta signaling pathway,M111,3,0
1,1,1,-3.2,-3.5,-5.5,GO:0045646,regulation of erythrocyte differentiation,M111,3,0
1,1,1,-4.7,-3.2,-2.4,WP3599,Transcription factor regulation in adipogenesis,M111,3,0
1,1,1,-5,-2.9,-3.7,GO:0071560,cellular response to transforming growth factor beta stimulus,M111,3,0
1,1,1,-2.5,-2.7,-4.5,hsa04660,T cell receptor signaling pathway,M111,3,0
1,1,1,-3.4,-2.5,-4.9,WP5102,Familial partial lipodystrophy,M111,3,0
1,1,1,-3.8,-6.2,-2.1,GO:0071773,cellular response to BMP stimulus,M111,3,0
1,1,1,-5.9,-3.6,-5.8,GO:0035113,embryonic appendage morphogenesis,M111,3,0
1,1,1,-7.8,-4.6,-6.7,GO:0048469,cell maturation,M111,3,0
1,1,1,-11,-6.9,-3.8,hsa05200,Pathways in cancer,M111,3,0
1,1,1,-3.4,-4.6,-6.3,GO:0045639,positive regulation of myeloid cell differentiation,M111,3,0
1,1,1,-10,-4.2,-4.6,R-HSA-9616222,Transcriptional regulation of granulopoiesis,M111,3,0
1,1,1,-3.9,-4.2,-6.5,M7,PID FCER1 PATHWAY,M111,3,0
1,1,1,-5.8,-3,-4.4,GO:0048736,appendage development,M111,3,0
1,1,1,-4.2,-3.8,-2.9,GO:0001818,negative regulation of cytokine production,M111,3,0
1,1,1,-4.7,-3.2,-2.2,M195,PID CMYB PATHWAY,M111,3,0
1,1,1,-15,-9,-4.6,GO:0043009,chordate embryonic development,M111,3,0
1,1,1,-3.4,-3,-5.9,GO:0046634,regulation of alpha-beta T cell activation,M111,3,0
1,1,1,-7.8,-5.2,-4.2,WP5373,Role of hypoxia angiogenesis and FGF pathway in OA chondrocyte hypertrophy,M111,3,0
1,1,1,-4.1,-3.5,-2.5,M235,PID TCR CALCIUM PATHWAY,M111,3,0
1,1,1,-9.1,-3,-3.4,hsa05202,Transcriptional misregulation in cancer,M111,3,0
1,1,1,-2.5,-3.4,-4.8,GO:0042113,B cell activation,M111,3,0
1,1,1,-3.9,-4.4,-3.9,R-HSA-2454202,Fc epsilon receptor (FCERI) signaling,M111,3,0
1,1,1,-3.7,-2.4,-2.4,M236,PID DELTA NP63 PATHWAY,M111,3,0
1,1,1,-3.9,-2.2,-2.9,M151,PID AR TF PATHWAY,M111,3,0
1,1,1,-2.4,-2.7,-3,GO:0050866,negative regulation of cell activation,M111,3,0
1,1,1,-8.5,-4.1,-3.1,GO:0061061,muscle structure development,M111,3,0
1,1,1,-2.9,-2.2,-2.4,GO:0010721,negative regulation of cell development,M111,3,0
1,1,1,-7.4,-6.4,-3.9,GO:0007167,enzyme-linked receptor protein signaling pathway,M111,3,0
1,1,1,-7.5,-4.1,-2.5,GO:0048880,sensory system development,M111,3,0
1,1,1,-5.9,-4.6,-6.1,GO:0002062,chondrocyte differentiation,M111,3,0
1,1,1,-10,-3.1,-6,hsa04380,Osteoclast differentiation,M111,3,0
1,1,1,-7.3,-6,-5.4,GO:0071345,cellular response to cytokine stimulus,M111,3,0
1,1,1,-3.8,-2.6,-3.1,R-HSA-2871809,FCERI mediated Ca+2 mobilization,M111,3,0
1,1,1,-3.3,-3.5,-2,GO:0002703,regulation of leukocyte mediated immunity,M111,3,0
1,1,1,-17,-8.9,-7.9,GO:0001501,skeletal system development,M111,3,0
1,1,1,-2.4,-3.3,-6,GO:0002768,immune response-regulating cell surface receptor signaling pathway,M111,3,0
1,1,1,-5.6,-3.6,-4.7,GO:0071559,response to transforming growth factor beta,M111,3,0
1,1,1,-4.5,-2.6,-4.6,R-HSA-9824443,Parasitic Infection Pathways,M111,3,0
1,1,1,-6.9,-4.7,-3,GO:0051960,regulation of nervous system development,M111,3,0
1,1,1,-7.6,-3.3,-11,GO:1903706,regulation of hemopoiesis,M111,3,0
1,1,1,-4.6,-3.2,-3.9,WP3945,TYROBP causal network in microglia,M111,3,0
1,1,1,-5.6,-3.8,-7.5,GO:0002694,regulation of leukocyte activation,M111,3,0
1,1,1,-4.5,-3.8,-4.6,GO:0045785,positive regulation of cell adhesion,M111,3,0
1,1,1,-3.2,-5.8,-2.4,GO:0071407,cellular response to organic cyclic compound,M111,3,0
1,1,1,-13,-13,-6.3,GO:0045165,cell fate commitment,M111,3,0
1,1,1,-16,-11,-15,GO:0030097,hemopoiesis,M111,3,0
1,1,1,-4.3,-2.7,-6,GO:0002696,positive regulation of leukocyte activation,M111,3,0
1,1,1,-5.8,-3,-9,GO:1902105,regulation of leukocyte differentiation,M111,3,0
1,1,1,-3.7,-2.7,-4.7,GO:0045621,positive regulation of lymphocyte differentiation,M111,3,0
1,1,1,-3.9,-2.4,-4.2,R-HSA-983705,Signaling by the B Cell Receptor (BCR),M111,3,0
1,1,1,-5.6,-3.4,-4.1,M272,PID CD8 TCR DOWNSTREAM PATHWAY,M111,3,0
1,1,1,-4,-4.8,-2.9,GO:1901699,cellular response to nitrogen compound,M111,3,0
1,1,1,-7.8,-5.4,-8.5,hsa05167,Kaposi sarcoma-associated herpesvirus infection,M111,3,0
1,1,1,-3.8,-2.9,-6.4,GO:0045619,regulation of lymphocyte differentiation,M111,3,0
1,1,1,-3.3,-2.7,-2.5,R-HSA-1257604,PIP3 activates AKT signaling,M111,3,0
1,1,1,-2.4,-2.9,-4.5,WP4304,Oligodendrocyte specification and differentiation leading to myelin components for CNS,M111,3,0
1,1,1,-7.6,-2.5,-2.7,WP706,Sudden infant death syndrome SIDS susceptibility pathways,M111,3,0
1,1,1,-10,-5.9,-2.1,GO:0035239,tube morphogenesis,M111,3,0
1,1,1,-7.1,-5.6,-7.2,WP23,B cell receptor signaling pathway,M111,3,0
1,1,1,-5.5,-3.5,-2.9,GO:0051962,positive regulation of nervous system development,M111,3,0
1,1,1,-3,-2.9,-4,WP69,T cell receptor signaling pathway,M111,3,0
1,1,1,-2.1,-3.4,-2.1,hsa05140,Leishmaniasis,M111,3,0
1,1,1,-4.4,-4.6,-2.8,GO:0007178,transmembrane receptor protein serine/threonine kinase signaling pathway,M111,3,0
1,1,1,-8.4,-7.7,-13,GO:0046649,lymphocyte activation,M111,3,0
1,1,1,-8.2,-2.4,-2.3,GO:0045444,fat cell differentiation,M111,3,0
1,1,1,-2.9,-2.8,-2.5,GO:1902692,regulation of neuroblast proliferation,M111,3,0
1,1,1,-8.4,-2.8,-4.5,GO:0048705,skeletal system morphogenesis,M111,3,0
1,1,1,-5.7,-5,-3.1,GO:0050767,regulation of neurogenesis,M111,3,0
1,1,1,-6.9,-5.2,-5.8,GO:0061351,neural precursor cell proliferation,M111,3,0
1,1,1,-2.1,-2.8,-3.5,CORUM:2694,ERG-JUN-FOS DNA-protein complex,M111,3,0
1,1,1,-8.5,-4.4,-4.6,GO:0045596,negative regulation of cell differentiation,M111,3,0
1,1,1,-6.3,-2.3,-4.1,GO:1904888,cranial skeletal system development,M111,3,0
1,1,1,-2.9,-3.2,-2.5,hsa05207,Chemical carcinogenesis - receptor activation,M111,3,0
1,1,1,-3.7,-4,-2.7,GO:0035050,embryonic heart tube development,M111,3,0
1,1,1,-5.4,-3.6,-5.1,GO:0045664,regulation of neuron differentiation,M111,3,0
1,1,1,-8.7,-8.5,-13,GO:0045321,leukocyte activation,M111,3,0
1,1,1,-2,-2.6,-2.5,hsa05211,Renal cell carcinoma,M111,3,0
1,1,1,-6,-8.1,-4.9,hsa04658,Th1 and Th2 cell differentiation,M111,3,0
1,1,1,-8.2,-3.9,-4.2,GO:0021537,telencephalon development,M111,3,0
1,1,1,-5.6,-3.3,-3.1,GO:0060538,skeletal muscle organ development,M111,3,0
1,1,1,-4.2,-3,-2.2,WP3972,PDGFR beta pathway,M111,3,0
1,1,1,-12,-6.7,-7.9,GO:0061448,connective tissue development,M111,3,0
1,1,1,-4.1,-5.8,-3.5,GO:0021953,central nervous system neuron differentiation,M111,3,0
1,1,1,-2.4,-4.5,-2.4,GO:0001890,placenta development,M111,3,0
1,1,1,-3.8,-3,-3.3,GO:0001503,ossification,M111,3,0
1,1,1,-5.9,-3.6,-5.8,GO:0030326,embryonic limb morphogenesis,M111,3,0
1,1,1,-3.4,-2.9,-4.8,GO:0045582,positive regulation of T cell differentiation,M111,3,0
1,1,1,-2.2,-5.2,-3.4,GO:0021872,forebrain generation of neurons,M111,3,0
1,1,1,-4.6,-5,-3.7,GO:0007405,neuroblast proliferation,M111,3,0
1,1,1,-5,-5.1,-2.2,GO:0090596,sensory organ morphogenesis,M111,3,0
1,1,1,-12,-5.5,-5,GO:1902893,regulation of miRNA transcription,M111,3,0
1,1,1,-6,-4,-5.3,GO:0035108,limb morphogenesis,M111,3,0
1,1,1,-6.6,-7.3,-4.2,WP3527,Pre implantation embryo,M111,3,0
1,1,1,-3.1,-3.2,-2.8,GO:0045666,positive regulation of neuron differentiation,M111,3,0
1,1,1,-2.7,-4.3,-3.8,WP5218,Extrafollicular and follicular B cell activation by SARS CoV 2,M111,3,0
1,1,1,-2.1,-3,-2.5,GO:0021895,cerebral cortex neuron differentiation,M111,3,0
1,1,1,-4,-3,-3,GO:0002366,leukocyte activation involved in immune response,M111,3,0
1,1,1,-2.4,-2.3,-4.3,GO:2000514,"regulation of CD4-positive, alpha-beta T cell activation",M111,3,0
1,1,1,-4.7,-3.1,-2.9,GO:0001708,cell fate specification,M111,3,0
1,1,1,-6,-5.6,-5.1,R-HSA-1280215,Cytokine Signaling in Immune system,M111,3,0
1,1,1,-3.9,-3.1,-6.4,GO:0046637,regulation of alpha-beta T cell differentiation,M111,3,0
1,1,1,-9.4,-7.7,-3.9,GO:0048598,embryonic morphogenesis,M111,3,0
1,1,1,-4,-2.1,-2.9,GO:0021987,cerebral cortex development,M111,3,0
1,1,1,-5.6,-3.9,-2.7,M10,PID BCR 5PATHWAY,M111,3,0
1,1,1,-4.8,-4.5,-6.3,GO:0002250,adaptive immune response,M111,3,0
1,1,1,-3.5,-2.7,-3.4,WP5198,Inflammatory bowel disease signaling,M111,3,0
1,1,1,-3.4,-4.4,-6.8,hsa05235,PD-L1 expression and PD-1 checkpoint pathway in cancer,M111,3,0
1,1,1,-8.4,-3.8,-4.6,GO:0048706,embryonic skeletal system development,M111,3,0
1,1,1,-6.6,-4,-2.6,WP4659,Gastrin signaling pathway,M111,3,0
1,1,1,-8.3,-4.2,-2.3,WP2064,Neural crest differentiation,M111,3,0
1,1,1,-12,-9.7,-14,GO:0002521,leukocyte differentiation,M111,3,0
1,1,1,-3,-2.2,-2,GO:2000179,positive regulation of neural precursor cell proliferation,M111,3,0
1,1,1,-3.8,-6.2,-2.1,GO:0071772,response to BMP,M111,3,0
1,1,1,-2.6,-2.2,-2.1,GO:0050868,negative regulation of T cell activation,M111,3,0
1,1,1,-3.4,-2.5,-2.3,WP5083,Neuroinflammation and glutamatergic signaling,M111,3,0
1,1,1,-4.7,-5.3,-3.2,GO:0042472,inner ear morphogenesis,M111,3,0
1,1,1,-4.8,-2.7,-2.1,WP4585,Cancer immunotherapy by PD 1 blockade,M111,3,0
1,1,1,-4.9,-2,-3,WP4879,Overlap between signal transduction pathways contributing to LMNA laminopathies,M111,3,0
1,1,0,-3.4,-2.2,0,GO:0090068,positive regulation of cell cycle process,M110,2,0
1,0,1,-2.1,0,-2.1,R-HSA-114604,GPVI-mediated activation cascade,M101,2,0
1,1,0,-3.9,-2.9,0,GO:1901652,response to peptide,M110,2,0
1,1,0,-4.7,-3.8,0,GO:0001837,epithelial to mesenchymal transition,M110,2,0
1,1,0,-2.6,-3.4,0,WP3967,miR 509 3p alteration of YAP1 ECM axis,M110,2,0
1,1,0,-3.7,-2.9,0,R-HSA-4090294,SUMOylation of intracellular receptors,M110,2,0
1,0,1,-4.3,0,-3.3,M54,PID IL12 2PATHWAY,M101,2,0
1,1,0,-2.3,-2.6,0,R-HSA-201681,TCF dependent signaling in response to WNT,M110,2,0
1,1,0,-5.6,-4.3,0,WP4337,ncRNAs involved in STAT3 signaling in hepatocellular carcinoma,M110,2,0
1,0,1,-2.7,0,-3.1,GO:0030888,regulation of B cell proliferation,M101,2,0
1,0,1,-2.8,0,-3.4,WP585,Interferon type I signaling pathways,M101,2,0
1,1,0,-2.4,-2.1,0,GO:0032495,response to muramyl dipeptide,M110,2,0
1,0,1,-4.1,0,-3.2,GO:0048709,oligodendrocyte differentiation,M101,2,0
1,1,0,-3,-3.8,0,GO:0007162,negative regulation of cell adhesion,M110,2,0
0,1,1,0,-2.1,-2.2,R-HSA-186763,Downstream signal transduction,M011,2,0
1,1,0,-2.5,-2.9,0,GO:0097529,myeloid leukocyte migration,M110,2,0
0,1,1,0,-3.4,-2.1,hsa04724,Glutamatergic synapse,M011,2,0
1,1,0,-6,-2.2,0,GO:0002067,glandular epithelial cell differentiation,M110,2,0
1,1,0,-8.1,-6,0,GO:0048729,tissue morphogenesis,M110,2,0
1,0,1,-2.9,0,-2.9,GO:0021766,hippocampus development,M101,2,0
0,1,1,0,-2.8,-5.2,GO:0097154,GABAergic neuron differentiation,M011,2,0
1,0,1,-2.7,0,-2.4,WP4216,Chromosomal and microsatellite instability in colorectal cancer,M101,2,0
1,1,0,-2.2,-2.5,0,GO:0042474,middle ear morphogenesis,M110,2,0
1,0,1,-3.1,0,-2.3,hsa05210,Colorectal cancer,M101,2,0
1,0,1,-2.7,0,-2.2,hsa05152,Tuberculosis,M101,2,0
1,1,0,-3.3,-3.8,0,hsa05224,Breast cancer,M110,2,0
1,1,0,-5.9,-3.3,0,GO:0009952,anterior/posterior pattern specification,M110,2,0
1,1,0,-4.3,-2.3,0,GO:0030324,lung development,M110,2,0
1,1,0,-2.6,-3.2,0,hsa05032,Morphine addiction,M110,2,0
1,1,0,-5.8,-2.1,0,WP170,Nuclear receptors,M110,2,0
1,1,0,-2.2,-2.9,0,WP5094,Orexin receptor pathway,M110,2,0
1,1,0,-4.7,-2.3,0,WP4482,Vitamin D in inflammatory diseases,M110,2,0
1,1,0,-4.5,-2.2,0,GO:0090102,cochlea development,M110,2,0
1,1,0,-2,-2.7,0,GO:0071774,response to fibroblast growth factor,M110,2,0
1,0,1,-3.6,0,-2.3,GO:0009617,response to bacterium,M101,2,0
1,1,0,-2.5,-4.1,0,GO:1901655,cellular response to ketone,M110,2,0
1,0,1,-2.2,0,-2.5,GO:0071425,hematopoietic stem cell proliferation,M101,2,0
1,0,1,-3,0,-2,WP2380,Brain derived neurotrophic factor BDNF signaling pathway,M101,2,0
1,1,0,-2.9,-2.1,0,GO:0045064,T-helper 2 cell differentiation,M110,2,0
1,0,1,-3,0,-2.3,GO:0035136,forelimb morphogenesis,M101,2,0
1,0,1,-2.2,0,-2.2,GO:0071248,cellular response to metal ion,M101,2,0
1,1,0,-3.8,-2.7,0,GO:0002053,positive regulation of mesenchymal cell proliferation,M110,2,0
1,1,0,-13,-7.5,0,WP2857,Mesodermal commitment pathway,M110,2,0
1,1,0,-2.4,-2.4,0,GO:0035162,embryonic hemopoiesis,M110,2,0
1,0,1,-6.9,0,-2.6,R-HSA-9031628,NGF-stimulated transcription,M101,2,0
1,1,0,-2.7,-2.5,0,GO:0048708,astrocyte differentiation,M110,2,0
1,1,0,-4.5,-3,0,GO:0002294,"CD4-positive, alpha-beta T cell differentiation involved in immune response",M110,2,0
1,1,0,-2.9,-2.5,0,GO:0072006,nephron development,M110,2,0
1,1,0,-2.5,-2.3,0,GO:0071375,cellular response to peptide hormone stimulus,M110,2,0
1,1,0,-2.2,-4.4,0,GO:0048864,stem cell development,M110,2,0
1,1,0,-2.6,-2.5,0,hsa04630,JAK-STAT signaling pathway,M110,2,0
1,1,0,-2.3,-2.7,0,GO:0060326,cell chemotaxis,M110,2,0
1,1,0,-2.1,-2.8,0,R-HSA-9673324,WNT5:FZD7-mediated leishmania damping,M110,2,0
1,1,0,-2.8,-2.3,0,WP2034,Leptin signaling pathway,M110,2,0
1,1,0,-2.2,-2,0,GO:0060070,canonical Wnt signaling pathway,M110,2,0
1,1,0,-2,-2.7,0,GO:0048332,mesoderm morphogenesis,M110,2,0
1,1,0,-5.2,-4.6,0,GO:0021772,olfactory bulb development,M110,2,0
1,0,1,-2.2,0,-4.9,M8626,SIG BCR SIGNALING PATHWAY,M101,2,0
1,1,0,-2.2,-2.7,0,GO:0035272,exocrine system development,M110,2,0
1,1,0,-2.6,-2.1,0,GO:1905330,regulation of morphogenesis of an epithelium,M110,2,0
1,1,0,-2.2,-2.3,0,GO:0046622,positive regulation of organ growth,M110,2,0
0,1,1,0,-2.2,-2.1,GO:0050807,regulation of synapse organization,M011,2,0
0,1,1,0,-5,-2.2,GO:0060078,regulation of postsynaptic membrane potential,M011,2,0
1,1,0,-3.1,-2.2,0,GO:0045927,positive regulation of growth,M110,2,0
1,1,0,-3.6,-3.8,0,GO:0060037,pharyngeal system development,M110,2,0
0,1,1,0,-2.4,-2.1,GO:0072124,regulation of glomerular mesangial cell proliferation,M011,2,0
1,1,0,-3.5,-3.4,0,R-HSA-3769402,Deactivation of the beta-catenin transactivating complex,M110,2,0
1,1,0,-2.2,-2.6,0,GO:0050731,positive regulation of peptidyl-tyrosine phosphorylation,M110,2,0
1,0,1,-2.6,0,-2.8,GO:0022030,telencephalon glial cell migration,M101,2,0
1,1,0,-3.7,-2.5,0,GO:0035710,"CD4-positive, alpha-beta T cell activation",M110,2,0
1,1,0,-7.9,-3.8,0,GO:0007507,heart development,M110,2,0
1,0,1,-6.7,0,-2.8,WP4666,Hepatitis B infection,M101,2,0
1,1,0,-4.2,-4.2,0,hsa04550,Signaling pathways regulating pluripotency of stem cells,M110,2,0
1,0,1,-3.1,0,-2.2,GO:0014013,regulation of gliogenesis,M101,2,0
1,1,0,-3,-2.8,0,GO:0030111,regulation of Wnt signaling pathway,M110,2,0
1,1,0,-4.2,-3.4,0,GO:0045787,positive regulation of cell cycle,M110,2,0
1,1,0,-7,-3.8,0,GO:0048514,blood vessel morphogenesis,M110,2,0
1,1,0,-3.6,-2.8,0,GO:0060041,retina development in camera-type eye,M110,2,0
0,1,1,0,-2.9,-2.8,hsa04935,"Growth hormone synthesis, secretion and action",M011,2,0
1,0,1,-2.3,0,-5.5,GO:0046635,positive regulation of alpha-beta T cell activation,M101,2,0
1,1,0,-2.4,-2.4,0,GO:0070741,response to interleukin-6,M110,2,0
1,1,0,-2.5,-2.3,0,R-HSA-5607764,CLEC7A (Dectin-1) signaling,M110,2,0
1,1,0,-6.2,-3.1,0,GO:0055123,digestive system development,M110,2,0
1,1,0,-5.2,-2.9,0,GO:0001822,kidney development,M110,2,0
1,1,0,-2.5,-2.1,0,GO:0032835,glomerulus development,M110,2,0
1,1,0,-6.4,-3.9,0,WP2853,Endoderm differentiation,M110,2,0
0,1,1,0,-3.2,-2.7,hsa04062,Chemokine signaling pathway,M011,2,0
0,1,1,0,-2.7,-4,M22,PID GMCSF PATHWAY,M011,2,0
1,0,1,-2.4,0,-3.2,R-HSA-9664433,Leishmania parasite growth and survival,M101,2,0
1,1,0,-7.2,-3.7,0,GO:0060537,muscle tissue development,M110,2,0
1,1,0,-2.1,-2.8,0,GO:0038154,interleukin-11-mediated signaling pathway,M110,2,0
1,1,0,-5,-3.6,0,GO:0002293,alpha-beta T cell differentiation involved in immune response,M110,2,0
1,1,0,-6.9,-3.2,0,GO:0022612,gland morphogenesis,M110,2,0
1,0,1,-2.2,0,-2.6,GO:0046533,negative regulation of photoreceptor cell differentiation,M101,2,0
1,1,0,-2.8,-4,0,GO:0055057,neuroblast division,M110,2,0
1,1,0,-2.2,-4.7,0,GO:0040034,"regulation of development, heterochronic",M110,2,0
1,0,1,-3,0,-2.5,GO:0022029,telencephalon cell migration,M101,2,0
1,1,0,-5.4,-4.3,0,GO:0007498,mesoderm development,M110,2,0
1,1,0,-3.9,-2.6,0,GO:0002520,immune system development,M110,2,0
1,1,0,-3,-4.5,0,GO:0043433,negative regulation of DNA-binding transcription factor activity,M110,2,0
1,0,1,-3.7,0,-5.1,GO:0002761,regulation of myeloid leukocyte differentiation,M101,2,0
0,1,1,0,-2.6,-2.5,GO:0032722,positive regulation of chemokine production,M011,2,0
1,1,0,-4,-3.5,0,R-HSA-157118,Signaling by NOTCH,M110,2,0
1,0,1,-3.4,0,-4.8,WP437,EGF EGFR signaling pathway,M101,2,0
0,1,1,0,-2.3,-8,WP286,IL 3 signaling pathway,M011,2,0
1,1,0,-3.8,-3,0,GO:0021675,nerve development,M110,2,0
1,1,0,-2.6,-2.1,0,GO:0097035,regulation of membrane lipid distribution,M110,2,0
1,0,1,-2.8,0,-2.2,R-HSA-5621481,C-type lectin receptors (CLRs),M101,2,0
0,1,1,0,-2.5,-2.2,hsa05323,Rheumatoid arthritis,M011,2,0
1,0,1,-3.3,0,-2.5,GO:0045665,negative regulation of neuron differentiation,M101,2,0
1,0,1,-3.4,0,-2.3,WP395,IL 4 signaling pathway,M101,2,0
1,1,0,-2.9,-2.8,0,WP2324,AGE RAGE pathway,M110,2,0
0,1,1,0,-3.2,-2.6,GO:0048589,developmental growth,M011,2,0
1,1,0,-3.6,-2.3,0,GO:0043586,tongue development,M110,2,0
1,1,0,-4.3,-3,0,GO:0045765,regulation of angiogenesis,M110,2,0
1,1,0,-2,-3.4,0,GO:0044706,multi-multicellular organism process,M110,2,0
1,1,0,-2.2,-2.5,0,GO:0021955,central nervous system neuron axonogenesis,M110,2,0
1,1,0,-6.7,-2.2,0,GO:0030879,mammary gland development,M110,2,0
1,1,0,-3.2,-3,0,GO:0061180,mammary gland epithelium development,M110,2,0
1,1,0,-4.6,-3.5,0,GO:0035019,somatic stem cell population maintenance,M110,2,0
1,0,1,-3,0,-2.2,R-HSA-9012999,RHO GTPase cycle,M101,2,0
1,1,0,-6.2,-4.7,0,GO:0003007,heart morphogenesis,M110,2,0
1,0,1,-3.8,0,-3.1,WP2203,Thymic stromal lymphopoietin TSLP signaling pathway,M101,2,0
1,0,1,-4.6,0,-4.6,GO:0048701,embryonic cranial skeleton morphogenesis,M101,2,0
1,1,0,-3.2,-2.7,0,M166,PID ATF2 PATHWAY,M110,2,0
1,1,0,-2.6,-4.4,0,GO:0048596,embryonic camera-type eye morphogenesis,M110,2,0
1,0,1,-4.3,0,-6.8,hsa04662,B cell receptor signaling pathway,M101,2,0
1,1,0,-5.5,-3.4,0,GO:0002292,T cell differentiation involved in immune response,M110,2,0
1,0,1,-2.8,0,-3.9,GO:0050670,regulation of lymphocyte proliferation,M101,2,0
1,1,0,-4.9,-4.4,0,GO:0021988,olfactory lobe development,M110,2,0
1,1,0,-3,-2.2,0,GO:0022404,molting cycle process,M110,2,0
1,1,0,-2.2,-2.5,0,GO:2001053,regulation of mesenchymal cell apoptotic process,M110,2,0
1,1,0,-4.1,-3,0,GO:0043367,"CD4-positive, alpha-beta T cell differentiation",M110,2,0
1,0,1,-2.8,0,-2.1,GO:0018212,peptidyl-tyrosine modification,M101,2,0
1,1,0,-5.3,-3.1,0,R-HSA-9758941,Gastrulation,M110,2,0
1,1,0,-3.7,-2.5,0,WP474,Endochondral ossification,M110,2,0
1,0,1,-4.1,0,-2.2,M223,PID BETA CATENIN NUC PATHWAY,M101,2,0
1,1,0,-5.1,-3.4,0,GO:0002286,T cell activation involved in immune response,M110,2,0
1,0,1,-2.5,0,-2.1,GO:0002443,leukocyte mediated immunity,M101,2,0
1,0,1,-3.2,0,-2.2,GO:0061371,determination of heart left/right asymmetry,M101,2,0
1,1,0,-3.9,-3.5,0,GO:0048754,branching morphogenesis of an epithelial tube,M110,2,0
0,1,1,0,-4.3,-3.4,WP3892,Development of pulmonary dendritic cells and macrophage subsets,M011,2,0
1,0,1,-2.2,0,-2.5,M241,PID RAC1 REG PATHWAY,M101,2,0
0,1,1,0,-3,-3.4,R-HSA-9725370,Signaling by ALK fusions and activated point mutants,M011,2,0
0,1,1,0,-3.4,-2.2,GO:0071383,cellular response to steroid hormone stimulus,M011,2,0
0,1,1,0,-3,-2.1,GO:0030225,macrophage differentiation,M011,2,0
1,0,1,-6.3,0,-3.4,R-HSA-198725,Nuclear Events (kinase and transcription factor activation),M101,2,0
1,1,0,-4.1,-3.9,0,GO:0072132,mesenchyme morphogenesis,M110,2,0
1,0,1,-8,0,-3.5,hsa05161,Hepatitis B,M101,2,0
1,1,0,-2.1,-2,0,GO:0001910,regulation of leukocyte mediated cytotoxicity,M110,2,0
0,1,1,0,-2.6,-3,GO:0032677,regulation of interleukin-8 production,M011,2,0
1,0,1,-3.4,0,-2.3,GO:0001947,heart looping,M101,2,0
0,1,1,0,-2.4,-2.1,WP5063,FOXP3 in COVID 19,M011,2,0
1,1,0,-3.9,-3.6,0,GO:0048638,regulation of developmental growth,M110,2,0
0,1,1,0,-2.3,-2.1,R-HSA-4086398,Ca2+ pathway,M011,2,0
0,1,1,0,-2.4,-2.1,GO:1901724,positive regulation of cell proliferation involved in kidney development,M011,2,0
1,1,0,-2.4,-2.8,0,R-HSA-1980143,Signaling by NOTCH1,M110,2,0
1,1,0,-2.6,-2.8,0,GO:0045669,positive regulation of osteoblast differentiation,M110,2,0
1,1,0,-3.8,-3.6,0,GO:0001704,formation of primary germ layer,M110,2,0
1,1,0,-2.5,-3.3,0,R-HSA-195721,Signaling by WNT,M110,2,0
1,0,1,-2.9,0,-2.1,GO:0048486,parasympathetic nervous system development,M101,2,0
1,1,0,-3,-2.2,0,GO:0022405,hair cycle process,M110,2,0
1,1,0,-4.9,-3.7,0,GO:0002697,regulation of immune effector process,M110,2,0
1,1,0,-8,-4.4,0,GO:0032774,RNA biosynthetic process,M110,2,0
1,1,0,-5.7,-2,0,GO:0030856,regulation of epithelial cell differentiation,M110,2,0
1,1,0,-3.5,-3,0,GO:0007369,gastrulation,M110,2,0
1,1,0,-6.7,-2.9,0,GO:0048565,digestive tract development,M110,2,0
1,1,0,-3.6,-2.9,0,GO:0003143,embryonic heart tube morphogenesis,M110,2,0
1,1,0,-2.3,-2.4,0,GO:0021532,neural tube patterning,M110,2,0
0,1,1,0,-2.3,-2.4,R-HSA-451326,Activation of kainate receptors upon glutamate binding,M011,2,0
1,1,0,-4.9,-4.9,0,GO:0045588,positive regulation of gamma-delta T cell differentiation,M110,2,0
1,0,1,-2,0,-2.5,WP3937,Microglia pathogen phagocytosis pathway,M101,2,0
1,1,0,-5.2,-2.4,0,GO:2000648,positive regulation of stem cell proliferation,M110,2,0
1,0,1,-2.2,0,-2.2,R-HSA-76002,"Platelet activation, signaling and aggregation",M101,2,0
1,1,0,-3,-2.4,0,GO:1903038,negative regulation of leukocyte cell-cell adhesion,M110,2,0
1,1,0,-5.4,-2.5,0,GO:0072189,ureter development,M110,2,0
1,1,0,-2.6,-2.1,0,GO:2000027,regulation of animal organ morphogenesis,M110,2,0
0,1,1,0,-2.9,-2.2,GO:0071277,cellular response to calcium ion,M011,2,0
1,0,1,-2.2,0,-2.6,GO:0043378,"positive regulation of CD8-positive, alpha-beta T cell differentiation",M101,2,0
1,0,1,-2.4,0,-2.9,GO:0050671,positive regulation of lymphocyte proliferation,M101,2,0
1,1,0,-4.2,-4.6,0,GO:0061138,morphogenesis of a branching epithelium,M110,2,0
1,0,1,-2.7,0,-2,hsa05162,Measles,M101,2,0
1,1,0,-2,-3.5,0,GO:0060759,regulation of response to cytokine stimulus,M110,2,0
1,0,1,-3.9,0,-2.7,GO:0002070,epithelial cell maturation,M101,2,0
1,1,0,-2.2,-4.7,0,GO:0048505,regulation of timing of cell differentiation,M110,2,0
0,1,1,0,-3,-2.2,GO:0043584,nose development,M011,2,0
0,1,1,0,-3.6,-2.7,GO:0021879,forebrain neuron differentiation,M011,2,0
0,1,1,0,-2.5,-4,M186,PID PDGFRB PATHWAY,M011,2,0
1,1,0,-4.7,-2.6,0,GO:0051336,regulation of hydrolase activity,M110,2,0
1,0,1,-2.2,0,-3.4,GO:0002763,positive regulation of myeloid leukocyte differentiation,M101,2,0
1,1,0,-4.1,-2.1,0,GO:0060872,semicircular canal development,M110,2,0
1,1,0,-2.5,-2.4,0,GO:0042476,odontogenesis,M110,2,0
1,1,0,-2.6,-2.3,0,GO:0061437,renal system vasculature development,M110,2,0
1,1,0,-5.5,-2.9,0,GO:0060840,artery development,M110,2,0
1,0,1,-3.3,0,-3.2,GO:0070663,regulation of leukocyte proliferation,M101,2,0
1,1,0,-2.5,-2.8,0,GO:0021952,central nervous system projection neuron axonogenesis,M110,2,0
1,1,0,-3.1,-3.8,0,GO:0051101,regulation of DNA binding,M110,2,0
0,1,1,0,-2.4,-2.1,GO:0046629,gamma-delta T cell activation,M011,2,0
0,1,1,0,-2.6,-2.3,WP3863,T cell antigen receptor TCR pathway during Staphylococcus aureus infection,M011,2,0
1,0,1,-2.1,0,-2.1,R-HSA-450282,MAPK targets/ Nuclear events mediated by MAP kinases,M101,2,0
1,1,0,-3.8,-3.4,0,GO:0060411,cardiac septum morphogenesis,M110,2,0
1,0,1,-2.6,0,-2.6,GO:0051250,negative regulation of lymphocyte activation,M101,2,0
1,1,0,-3.2,-3.2,0,WP4262,Breast cancer pathway,M110,2,0
1,1,0,-2.4,-3.1,0,GO:0043300,regulation of leukocyte degranulation,M110,2,0
1,1,0,-2.3,-2.2,0,GO:0035282,segmentation,M110,2,0
1,0,1,-2.4,0,-3.2,R-HSA-9662851,Anti-inflammatory response favouring Leishmania parasite infection,M101,2,0
1,0,1,-2,0,-2.5,GO:0031343,positive regulation of cell killing,M101,2,0
1,1,0,-2.1,-2.7,0,GO:0071353,cellular response to interleukin-4,M110,2,0
1,1,0,-4.5,-5.4,0,WP4540,Hippo signaling regulation pathways,M110,2,0
0,1,1,0,-2.4,-2.1,GO:2001187,"positive regulation of CD8-positive, alpha-beta T cell activation",M011,2,0
1,1,0,-4.1,-2.3,0,GO:0060443,mammary gland morphogenesis,M110,2,0
1,1,0,-2.6,-3.4,0,GO:0060603,mammary gland duct morphogenesis,M110,2,0
1,1,0,-2.2,-2.5,0,M23,PID WNT NONCANONICAL PATHWAY,M110,2,0
1,1,0,-4.2,-3.6,0,GO:0040008,regulation of growth,M110,2,0
0,1,1,0,-2.1,-3.2,WP313,Hepatocyte growth factor receptor signaling,M011,2,0
0,1,1,0,-2.7,-3,R-HSA-9674555,Signaling by CSF3 (G-CSF),M011,2,0
1,1,0,-2.6,-2.3,0,GO:0061440,kidney vasculature development,M110,2,0
1,1,0,-2,-3.2,0,GO:1904892,regulation of receptor signaling pathway via STAT,M110,2,0
1,1,0,-3.8,-2.7,0,GO:0043588,skin development,M110,2,0
1,1,0,-8.6,-5.6,0,GO:0006366,transcription by RNA polymerase II,M110,2,0
1,0,1,-2.2,0,-3,GO:0021515,cell differentiation in spinal cord,M101,2,0
1,0,1,-2.7,0,-3.4,WP2023,Cell differentiation expanded index,M101,2,0
0,1,1,0,-2.3,-3,R-HSA-451308,Activation of Ca-permeable Kainate Receptor,M011,2,0
1,0,1,-4.3,0,-2.5,hsa04625,C-type lectin receptor signaling pathway,M101,2,0
1,1,0,-3.5,-2.9,0,WP2882,Nuclear receptors meta pathway,M110,2,0
1,0,1,-3.4,0,-2.1,hsa04921,Oxytocin signaling pathway,M101,2,0
0,1,1,0,-2.4,-3.6,WP4205,MET in type 1 papillary renal cell carcinoma,M011,2,0
1,1,0,-4.8,-2.5,0,GO:0030323,respiratory tube development,M110,2,0
1,1,0,-4.4,-2.8,0,GO:1901342,regulation of vasculature development,M110,2,0
1,1,0,-2.9,-2.1,0,GO:0021889,olfactory bulb interneuron differentiation,M110,2,0
1,1,0,-2.1,-2.8,0,GO:0060136,embryonic process involved in female pregnancy,M110,2,0
1,0,1,-2.4,0,-2.5,GO:1902074,response to salt,M101,2,0
1,1,0,-4.3,-2.2,0,hsa04151,PI3K-Akt signaling pathway,M110,2,0
0,1,1,0,-3.2,-2.6,GO:0040007,growth,M011,2,0
1,1,0,-2.4,-2.7,0,GO:1901653,cellular response to peptide,M110,2,0
1,0,1,-2.4,0,-2.9,hsa05135,Yersinia infection,M101,2,0
1,0,1,-2.5,0,-2.8,GO:0032946,positive regulation of mononuclear cell proliferation,M101,2,0
1,1,0,-6.2,-3,0,R-HSA-400253,Circadian Clock,M110,2,0
1,1,0,-3.7,-3.4,0,GO:0003279,cardiac septum development,M110,2,0
1,1,0,-5.8,-7.5,0,GO:0060485,mesenchyme development,M110,2,0
0,1,1,0,-3.4,-4.1,GO:0002253,activation of immune response,M011,2,0
1,1,0,-3.8,-2.8,0,GO:0002285,lymphocyte activation involved in immune response,M110,2,0
1,0,1,-3.1,0,-2.1,WP2877,Vitamin D receptor pathway,M101,2,0
1,1,0,-3.5,-2.7,0,GO:0008544,epidermis development,M110,2,0
1,1,0,-3.3,-3.2,0,GO:0031214,biomineral tissue development,M110,2,0
1,0,1,-2.4,0,-4.1,R-HSA-9664323,FCGR3A-mediated IL10 synthesis,M101,2,0
1,0,1,-3.1,0,-2.5,GO:0021846,cell proliferation in forebrain,M101,2,0
1,1,0,-4,-3.1,0,WP4541,Hippo Merlin signaling dysregulation,M110,2,0
1,1,0,-4.1,-4.3,0,GO:0046645,positive regulation of gamma-delta T cell activation,M110,2,0
1,0,1,-2.8,0,-2.3,GO:0048385,regulation of retinoic acid receptor signaling pathway,M101,2,0
0,1,1,0,-2.3,-2.9,WP364,IL6 signaling pathway,M011,2,0
1,0,1,-2.4,0,-2.9,hsa05223,Non-small cell lung cancer,M101,2,0
1,1,0,-4,-3.8,0,GO:0048048,embryonic eye morphogenesis,M110,2,0
1,0,1,-3.5,0,-2.7,GO:0002069,columnar/cuboidal epithelial cell maturation,M101,2,0
1,1,0,-9.8,-4.1,0,GO:0048732,gland development,M110,2,0
1,1,0,-3.1,-3.7,0,GO:0010594,regulation of endothelial cell migration,M110,2,0
1,1,0,-2.6,-3.4,0,GO:0070670,response to interleukin-4,M110,2,0
1,0,1,-2.1,0,-2.1,GO:0021510,spinal cord development,M101,2,0
1,1,0,-3.7,-2.5,0,WP4808,Endochondral ossification with skeletal dysplasias,M110,2,0
1,1,0,-3.6,-2.3,0,GO:0030216,keratinocyte differentiation,M110,2,0
1,0,1,-4.1,0,-2.6,M279,PID RB 1PATHWAY,M101,2,0
1,1,0,-2.7,-2,0,GO:0042303,molting cycle,M110,2,0
1,0,1,-2.6,0,-3.8,hsa04664,Fc epsilon RI signaling pathway,M101,2,0
1,1,0,-5.5,-5.4,0,GO:0048762,mesenchymal cell differentiation,M110,2,0
1,1,0,-2.8,-2.2,0,GO:2000737,negative regulation of stem cell differentiation,M110,2,0
1,1,0,-4.3,-3.9,0,GO:1901654,response to ketone,M110,2,0
1,1,0,-4.1,-3.6,0,GO:0003206,cardiac chamber morphogenesis,M110,2,0
0,1,1,0,-2.9,-3.5,WP5115,Network map of SARS CoV 2 signaling pathway,M011,2,0
0,1,1,0,-2.1,-3.4,R-HSA-1280218,Adaptive Immune System,M011,2,0
1,1,0,-2.8,-2.3,0,GO:0071499,cellular response to laminar fluid shear stress,M110,2,0
1,1,0,-6.3,-2.4,0,GO:0030522,intracellular receptor signaling pathway,M110,2,0
1,1,0,-3.3,-4.7,0,GO:0019827,stem cell population maintenance,M110,2,0
1,1,0,-2.6,-3.6,0,R-HSA-2559582,Senescence-Associated Secretory Phenotype (SASP),M110,2,0
1,1,0,-2.8,-2.3,0,WP3299,let 7 inhibition of ES cell reprogramming,M110,2,0
1,0,1,-2.8,0,-4.4,R-HSA-983695,Antigen activates B Cell Receptor (BCR) leading to generation of second messengers,M101,2,0
1,1,0,-3.3,-4.9,0,GO:0098727,maintenance of cell number,M110,2,0
1,1,0,-2.9,-2.4,0,GO:0022408,negative regulation of cell-cell adhesion,M110,2,0
0,1,1,0,-2.2,-2,GO:0050852,T cell receptor signaling pathway,M011,2,0
1,1,0,-7.4,-5.4,0,GO:0002009,morphogenesis of an epithelium,M110,2,0
0,1,1,0,-2.1,-3.2,R-HSA-9705462,Inactivation of CSF3 (G-CSF) signaling,M011,2,0
1,1,0,-3.5,-2.2,0,GO:0031016,pancreas development,M110,2,0
1,1,0,-3.3,-2.3,0,GO:0002698,negative regulation of immune effector process,M110,2,0
1,0,1,-3.9,0,-2.2,WP3611,Photodynamic therapy induced AP 1 survival signaling,M101,2,0
1,0,1,-2.9,0,-2.1,M36,PID IL27 PATHWAY,M101,2,0
1,1,0,-3,-2.9,0,GO:0031076,embryonic camera-type eye development,M110,2,0
0,1,1,0,-3.1,-5.4,GO:0002429,immune response-activating cell surface receptor signaling pathway,M011,2,0
1,1,0,-7.8,-4.5,0,GO:0006351,DNA-templated transcription,M110,2,0
0,1,1,0,-2.1,-4.3,R-HSA-912631,Regulation of signaling by CBL,M011,2,0
1,0,1,-2,0,-3,GO:0051384,response to glucocorticoid,M101,2,0
1,1,0,-2.4,-2.8,0,hsa04640,Hematopoietic cell lineage,M110,2,0
1,1,0,-3.4,-3.5,0,WP2858,Ectoderm differentiation,M110,2,0
1,0,1,-3.5,0,-2.6,GO:0021800,cerebral cortex tangential migration,M101,2,0
1,1,0,-2.4,-2.4,0,R-HSA-112315,Transmission across Chemical Synapses,M110,2,0
1,1,0,-2.2,-2.9,0,hsa04310,Wnt signaling pathway,M110,2,0
1,0,1,-4.3,0,-2.2,WP2018,RANKL RANK signaling pathway,M101,2,0
1,1,0,-3.4,-2.3,0,M28,PID IL4 2PATHWAY,M110,2,0
1,0,1,-3.4,0,-3.2,GO:0021780,glial cell fate specification,M101,2,0
1,1,0,-4.3,-2.6,0,WP3932,Focal adhesion PI3K Akt mTOR signaling pathway,M110,2,0
0,1,1,0,-2.3,-4.7,R-HSA-512988,"Interleukin-3, Interleukin-5 and GM-CSF signaling",M011,2,0
1,1,0,-2.6,-2.1,0,GO:0050900,leukocyte migration,M110,2,0
1,1,0,-2.8,-2.3,0,GO:0032763,regulation of mast cell cytokine production,M110,2,0
1,1,0,-6.6,-2.9,0,R-HSA-381340,Transcriptional regulation of white adipocyte differentiation,M110,2,0
1,1,0,-2,-2.3,0,GO:0001936,regulation of endothelial cell proliferation,M110,2,0
1,1,0,-2.1,-2.8,0,GO:0002704,negative regulation of leukocyte mediated immunity,M110,2,0
1,1,0,-6.3,-3.7,0,GO:0060541,respiratory system development,M110,2,0
1,1,0,-4,-3.4,0,WP5087,Pleural mesothelioma,M110,2,0
0,1,1,0,-2.1,-2.4,hsa04072,Phospholipase D signaling pathway,M011,2,0
0,1,1,0,-2.8,-4.2,GO:0045648,positive regulation of erythrocyte differentiation,M011,2,0
1,1,0,-3,-2.2,0,GO:0002052,positive regulation of neuroblast proliferation,M110,2,0
1,1,0,-5.7,-6.2,0,WP2374,Oncostatin M signaling pathway,M110,2,0
1,0,1,-2.8,0,-2.7,GO:0007219,Notch signaling pathway,M101,2,0
0,1,1,0,-2.2,-2.1,GO:0050803,regulation of synapse structure or activity,M011,2,0
0,1,1,0,-2.1,-3,WP3630,NAD metabolism sirtuins and aging,M011,2,0
0,1,1,0,-3.1,-3,R-HSA-8951430,RUNX3 regulates WNT signaling,M011,2,0
0,1,1,0,-2.3,-3,GO:0043380,regulation of memory T cell differentiation,M011,2,0
1,0,1,-2,0,-2.8,GO:0071241,cellular response to inorganic substance,M101,2,0
1,1,0,-2.6,-2.1,0,GO:0002699,positive regulation of immune effector process,M110,2,0
1,0,1,-2.8,0,-2.3,GO:0002071,glandular epithelial cell maturation,M101,2,0
1,1,0,-2.1,-2.3,0,GO:0001656,metanephros development,M110,2,0
1,1,0,-4.9,-3.7,0,GO:0001709,cell fate determination,M110,2,0
1,1,0,-3.5,-2.3,0,GO:0045667,regulation of osteoblast differentiation,M110,2,0
1,1,0,-4,-5.1,0,GO:0001763,morphogenesis of a branching structure,M110,2,0
1,0,1,-3.9,0,-3.3,GO:0021795,cerebral cortex cell migration,M101,2,0
1,1,0,-4.7,-3.9,0,GO:0045586,regulation of gamma-delta T cell differentiation,M110,2,0
1,0,1,-3.3,0,-3.1,hsa04218,Cellular senescence,M101,2,0
0,1,1,0,-3.7,-4.9,GO:0002757,immune response-activating signaling pathway,M011,2,0
0,1,1,0,-2.3,-2.1,GO:0042475,odontogenesis of dentin-containing tooth,M011,2,0
1,0,1,-2.2,0,-2.7,GO:0050864,regulation of B cell activation,M101,2,0
1,1,0,-2.2,-2.3,0,WP3303,RAC1 PAK1 p38 MMP2 pathway,M110,2,0
1,1,0,-2.6,-2.2,0,R-HSA-2122947,NOTCH1 Intracellular Domain Regulates Transcription,M110,2,0
0,1,1,0,-2.5,-2.1,GO:0060760,positive regulation of response to cytokine stimulus,M011,2,0
1,0,1,-3.8,0,-2.1,GO:0090103,cochlea morphogenesis,M101,2,0
1,1,0,-4.5,-2.2,0,WP4172,PI3K Akt signaling pathway,M110,2,0
1,1,0,-6.9,-8,0,GO:0048863,stem cell differentiation,M110,2,0
1,1,0,-4.1,-3.5,0,GO:0046643,regulation of gamma-delta T cell activation,M110,2,0
1,0,1,-2.6,0,-2.8,WP127,IL 5 signaling pathway,M101,2,0
1,1,0,-3.9,-2.1,0,GO:0001525,angiogenesis,M110,2,0
1,0,1,-2.5,0,-2.9,GO:0002819,regulation of adaptive immune response,M101,2,0
1,1,0,-4,-3.1,0,GO:0003205,cardiac chamber development,M110,2,0
1,0,1,-3.6,0,-2.5,GO:0035115,embryonic forelimb morphogenesis,M101,2,0
1,1,0,-2.3,-2.4,0,GO:1903305,regulation of regulated secretory pathway,M110,2,0
0,1,1,0,-2.1,-2.2,hsa04514,Cell adhesion molecules,M011,2,0
1,0,1,-4.8,0,-4,M17200,SA B CELL RECEPTOR COMPLEXES,M101,2,0
1,1,0,-5.1,-4.9,0,GO:0060562,epithelial tube morphogenesis,M110,2,0
1,1,0,-2.1,-2.5,0,GO:0022604,regulation of cell morphogenesis,M110,2,0
1,0,1,-2.8,0,-2.2,WP4255,Non small cell lung cancer,M101,2,0
1,0,1,-2.2,0,-2.6,GO:0021529,spinal cord oligodendrocyte cell differentiation,M101,2,0
1,0,1,-2.2,0,-2.6,WP4928,MAPK pathway in congenital thyroid cancer,M101,2,0
0,1,1,0,-2.4,-2.1,R-HSA-1839117,Signaling by cytosolic FGFR1 fusion mutants,M011,2,0
1,0,1,-2.4,0,-3.1,GO:0021799,cerebral cortex radially oriented cell migration,M101,2,0
1,1,0,-2.2,-3.1,0,GO:0042492,gamma-delta T cell differentiation,M110,2,0
1,1,0,-2.1,-2,0,GO:0060688,regulation of morphogenesis of a branching structure,M110,2,0
1,1,0,-3.2,-2.1,0,GO:0072073,kidney epithelium development,M110,2,0
1,0,1,-2.8,0,-2.3,GO:0060397,growth hormone receptor signaling pathway via JAK-STAT,M101,2,0
1,0,1,-2.2,0,-2.6,GO:0046532,regulation of photoreceptor cell differentiation,M101,2,0
1,0,1,-2.8,0,-2.1,GO:0018108,peptidyl-tyrosine phosphorylation,M101,2,0
1,1,0,-3.5,-2.8,0,GO:1902532,negative regulation of intracellular signal transduction,M110,2,0
1,1,0,-3.9,-2.3,0,M255,PID HIF1 TFPATHWAY,M110,2,0
1,0,1,-2.4,0,-3.1,M91,PID TCPTP PATHWAY,M101,2,0
1,1,0,-2.2,-2.5,0,GO:0051098,regulation of binding,M110,2,0
1,0,1,-2.2,0,-6,GO:0046638,positive regulation of alpha-beta T cell differentiation,M101,2,0
1,1,0,-2.7,-2,0,GO:0042633,hair cycle,M110,2,0
1,0,1,-4.1,0,-3.3,GO:0021602,cranial nerve morphogenesis,M101,2,0
1,0,1,-3.2,0,-2.4,GO:0021885,forebrain cell migration,M101,2,0
1,1,0,-4.4,-4.9,0,GO:0002064,epithelial cell development,M110,2,0
0,1,1,0,-3,-3.4,R-HSA-9700206,Signaling by ALK in cancer,M011,2,0
1,0,1,-4.9,0,-5,GO:0048871,multicellular organismal-level homeostasis,M101,2,0
1,1,0,-2.8,-2.2,0,GO:0032703,negative regulation of interleukin-2 production,M110,2,0
0,1,1,0,-5.5,-2.1,GO:0071396,cellular response to lipid,M011,2,0
1,0,1,-2.8,0,-3.4,GO:0042088,T-helper 1 type immune response,M101,2,0
1,1,0,-5,-3.6,0,GO:0002287,alpha-beta T cell activation involved in immune response,M110,2,0
0,1,1,0,-3,-4.2,WP5098,T cell activation SARS CoV 2,M011,2,0
1,0,1,-4.1,0,-2.6,GO:0060349,bone morphogenesis,M101,2,0
1,1,0,-2.3,-2.9,0,GO:0007565,female pregnancy,M110,2,0
1,0,1,-2.8,0,-2.2,GO:0050871,positive regulation of B cell activation,M101,2,0
1,1,0,-2.4,-5.1,0,GO:0048339,paraxial mesoderm development,M110,2,0
1,0,1,-3,0,-3.8,GO:0032944,regulation of mononuclear cell proliferation,M101,2,0
0,1,1,0,-4.1,-3.4,GO:0001819,positive regulation of cytokine production,M011,2,0
1,0,1,-2.6,0,-2.8,GO:0021801,cerebral cortex radial glia-guided migration,M101,2,0
0,1,1,0,-2.3,-3,R-HSA-451306,Ionotropic activity of kainate receptors,M011,2,0
1,1,0,-3,-2.4,0,WP5053,Development of ureteric collection system,M110,2,0
1,1,0,-2.6,-3.2,0,GO:0032663,regulation of interleukin-2 production,M110,2,0
1,1,0,-2.1,-2.8,0,R-HSA-8849473,PTK6 Expression,M110,2,0
1,1,0,-6,-3.2,0,GO:0072001,renal system development,M110,2,0
1,1,0,-4.5,-3,0,GO:0042093,T-helper cell differentiation,M110,2,0
1,1,0,-2.1,-2.8,0,R-HSA-9664420,Killing mechanisms,M110,2,0
1,1,0,-2.7,-2.5,0,GO:0031341,regulation of cell killing,M110,2,0
1,1,0,-5.5,-2.2,0,GO:0002244,hematopoietic progenitor cell differentiation,M110,2,0
0,1,1,0,-3.8,-5.3,GO:0002764,immune response-regulating signaling pathway,M011,2,0
1,1,0,-2.7,-2.3,0,R-HSA-8853884,Transcriptional Regulation by VENTX,M110,2,0
1,0,1,-3.1,0,-2.7,M1315,SIG PIP3 SIGNALING IN B LYMPHOCYTES,M101,2,0
0,1,1,0,-4.8,-2.6,GO:0032102,negative regulation of response to external stimulus,M011,2,0
1,1,0,-3.4,-2.8,0,M164,PID ERBB1 DOWNSTREAM PATHWAY,M110,2,0
0,1,1,0,-2.5,-6.1,M290,PID IL12 STAT4 PATHWAY,M011,2,0
1,1,0,-7.5,-5.2,0,GO:0003151,outflow tract morphogenesis,M110,2,0
1,0,1,-3.1,0,-3.4,GO:0002695,negative regulation of leukocyte activation,M101,2,0
1,1,0,-2.1,-3,0,GO:0044703,multi-organism reproductive process,M110,2,0
0,1,1,0,-3.3,-2.8,GO:0032655,regulation of interleukin-12 production,M011,2,0
1,0,1,-2.4,0,-2.2,GO:0060216,definitive hemopoiesis,M101,2,0
1,1,0,-3.4,-3.2,0,GO:0010632,regulation of epithelial cell migration,M110,2,0
1,1,0,-2.1,-2.8,0,GO:0033262,regulation of nuclear cell cycle DNA replication,M110,2,0
1,0,0,-2.1,0,0,GO:0060976,coronary vasculature development,M100,1,0
0,1,0,0,-2.4,0,GO:0060079,excitatory postsynaptic potential,M010,1,0
1,0,0,-3.9,0,0,GO:0009855,determination of bilateral symmetry,M100,1,0
1,0,0,-2.2,0,0,GO:0046546,development of primary male sexual characteristics,M100,1,0
0,0,1,0,0,-2.3,GO:1900016,negative regulation of cytokine production involved in inflammatory response,M001,1,0
0,1,0,0,-2.2,0,GO:0048145,regulation of fibroblast proliferation,M010,1,0
1,0,0,-2.4,0,0,GO:0051146,striated muscle cell differentiation,M100,1,0
0,0,1,0,0,-2.1,WP4816,TGF beta receptor signaling in skeletal dysplasias,M001,1,0
1,0,0,-2.6,0,0,M33,PID GLYPICAN 1PATHWAY,M100,1,0
1,0,0,-6.3,0,0,hsa04010,MAPK signaling pathway,M100,1,0
1,0,0,-2.2,0,0,GO:0003198,epithelial to mesenchymal transition involved in endocardial cushion formation,M100,1,0
0,1,0,0,-3.2,0,R-HSA-9682385,FLT3 signaling in disease,M010,1,0
0,1,0,0,-2.9,0,WP4222,Phosphodiesterases in neuronal function,M010,1,0
0,1,0,0,-2.3,0,GO:0072107,positive regulation of ureteric bud formation,M010,1,0
1,0,0,-3.8,0,0,R-HSA-5617472,Activation of anterior HOX genes in hindbrain development during early embryogenesis,M100,1,0
0,1,0,0,-2.4,0,GO:0051785,positive regulation of nuclear division,M010,1,0
0,1,0,0,-2.1,0,R-HSA-8852135,Protein ubiquitination,M010,1,0
1,0,0,-2.6,0,0,M92,PID ANGIOPOIETIN RECEPTOR PATHWAY,M100,1,0
1,0,0,-2.1,0,0,GO:0070668,positive regulation of mast cell proliferation,M100,1,0
0,1,0,0,-2.8,0,GO:0030865,cortical cytoskeleton organization,M010,1,0
1,0,0,-3.5,0,0,GO:0001101,response to acid chemical,M100,1,0
0,1,0,0,-2.8,0,GO:0034391,regulation of smooth muscle cell apoptotic process,M010,1,0
1,0,0,-4.9,0,0,WP3995,Prion disease pathway,M100,1,0
0,1,0,0,-3.2,0,GO:0090287,regulation of cellular response to growth factor stimulus,M010,1,0
1,0,0,-4.8,0,0,GO:0009755,hormone-mediated signaling pathway,M100,1,0
1,0,0,-2.8,0,0,CORUM:5230,CHUK-NFKB2-REL-IKBKG-SPAG9-NFKB1-NFKBIE-COPB2-TNIP1-NFKBIA-RELA-TNIP2 complex,M100,1,0
0,1,0,0,-2.1,0,M268,PID S1P S1P2 PATHWAY,M010,1,0
0,1,0,0,-2.3,0,GO:0048541,Peyer's patch development,M010,1,0
0,1,0,0,-2.1,0,R-HSA-8878171,Transcriptional regulation by RUNX1,M010,1,0
0,0,1,0,0,-2.6,R-HSA-9027276,Erythropoietin activates Phosphoinositide-3-kinase (PI3K),M001,1,0
1,0,0,-2.8,0,0,hsa04920,Adipocytokine signaling pathway,M100,1,0
1,0,0,-2.1,0,0,CORUM:5464,IKBA-p50-p65 Nf(kappa)B complex,M100,1,0
1,0,0,-2.4,0,0,WP5180,DYRK1A involvement regarding cell proliferation in brain development,M100,1,0
0,1,0,0,-2.4,0,GO:0019722,calcium-mediated signaling,M010,1,0
0,1,0,0,-2.5,0,GO:0070233,negative regulation of T cell apoptotic process,M010,1,0
1,0,0,-2.2,0,0,GO:0060444,branching involved in mammary gland duct morphogenesis,M100,1,0
1,0,0,-2.3,0,0,GO:0009310,amine catabolic process,M100,1,0
0,1,0,0,-3.7,0,WP428,Wnt signaling,M010,1,0
0,1,0,0,-4.8,0,GO:0097485,neuron projection guidance,M010,1,0
1,0,0,-2.5,0,0,WP4963,p53 transcriptional gene network,M100,1,0
1,0,0,-2.2,0,0,GO:0002708,positive regulation of lymphocyte mediated immunity,M100,1,0
1,0,0,-2.8,0,0,GO:0010718,positive regulation of epithelial to mesenchymal transition,M100,1,0
1,0,0,-4.4,0,0,GO:0035909,aorta morphogenesis,M100,1,0
1,0,0,-2.7,0,0,WP5381,Smith Magenis and Potocki Lupski syndrome copy number variation,M100,1,0
0,1,0,0,-2.3,0,M41,PID ER NONGENOMIC PATHWAY,M010,1,0
0,1,0,0,-3.8,0,GO:0048341,paraxial mesoderm formation,M010,1,0
0,1,0,0,-2.8,0,WP4542,Leukocyte intrinsic Hippo pathway functions,M010,1,0
0,1,0,0,-2.1,0,GO:0006469,negative regulation of protein kinase activity,M010,1,0
0,1,0,0,-2.1,0,GO:0070372,regulation of ERK1 and ERK2 cascade,M010,1,0
1,0,0,-2.2,0,0,GO:0060251,regulation of glial cell proliferation,M100,1,0
1,0,0,-2.8,0,0,WP3655,Hypothetical craniofacial development pathway,M100,1,0
0,1,0,0,-2.6,0,M276,PID FGF PATHWAY,M010,1,0
1,0,0,-2.1,0,0,GO:0007028,cytoplasm organization,M100,1,0
0,0,1,0,0,-2.1,GO:1903725,regulation of phospholipid metabolic process,M001,1,0
0,1,0,0,-2.7,0,GO:0098609,cell-cell adhesion,M010,1,0
1,0,0,-2.8,0,0,R-HSA-9013149,RAC1 GTPase cycle,M100,1,0
1,0,0,-2.1,0,0,GO:0043435,response to corticotropin-releasing hormone,M100,1,0
1,0,0,-5.1,0,0,GO:0060348,bone development,M100,1,0
1,0,0,-2.7,0,0,GO:0072009,nephron epithelium development,M100,1,0
1,0,0,-2.2,0,0,GO:0034504,protein localization to nucleus,M100,1,0
1,0,0,-2.5,0,0,GO:0003310,pancreatic A cell differentiation,M100,1,0
1,0,0,-2.5,0,0,GO:0019217,regulation of fatty acid metabolic process,M100,1,0
1,0,0,-2.3,0,0,GO:0071901,negative regulation of protein serine/threonine kinase activity,M100,1,0
1,0,0,-3,0,0,R-HSA-9013508,NOTCH3 Intracellular Domain Regulates Transcription,M100,1,0
1,0,0,-3.1,0,0,GO:0006306,DNA methylation,M100,1,0
0,1,0,0,-3.6,0,GO:0060711,labyrinthine layer development,M010,1,0
1,0,0,-2.1,0,0,GO:0110022,regulation of cardiac muscle myoblast proliferation,M100,1,0
0,0,1,0,0,-2.5,GO:0002831,regulation of response to biotic stimulus,M001,1,0
0,1,0,0,-2.1,0,GO:0030903,notochord development,M010,1,0
0,1,0,0,-2.3,0,R-HSA-6807070,PTEN Regulation,M010,1,0
1,0,0,-2.7,0,0,R-HSA-168142,Toll Like Receptor 10 (TLR10) Cascade,M100,1,0
0,0,1,0,0,-2.3,GO:0021517,ventral spinal cord development,M001,1,0
0,1,0,0,-2.3,0,GO:0040011,locomotion,M010,1,0
0,1,0,0,-2.3,0,GO:0061045,negative regulation of wound healing,M010,1,0
0,0,1,0,0,-2.9,GO:0032757,positive regulation of interleukin-8 production,M001,1,0
0,1,0,0,-2.5,0,GO:0002478,antigen processing and presentation of exogenous peptide antigen,M010,1,0
0,0,1,0,0,-2.8,GO:0045087,innate immune response,M001,1,0
0,0,1,0,0,-2.5,R-HSA-388841,Costimulation by the CD28 family,M001,1,0
0,1,0,0,-2.8,0,GO:0098696,regulation of neurotransmitter receptor localization to postsynaptic specialization membrane,M010,1,0
1,0,0,-3.1,0,0,GO:0061035,regulation of cartilage development,M100,1,0
0,0,1,0,0,-2.9,GO:0043299,leukocyte degranulation,M001,1,0
0,0,1,0,0,-2.1,GO:0071236,cellular response to antibiotic,M001,1,0
1,0,0,-3.3,0,0,WP4241,Type 2 papillary renal cell carcinoma,M100,1,0
0,1,0,0,-2.1,0,GO:0060074,synapse maturation,M010,1,0
1,0,0,-2.1,0,0,GO:0071376,cellular response to corticotropin-releasing hormone stimulus,M100,1,0
0,1,0,0,-3.5,0,GO:0014033,neural crest cell differentiation,M010,1,0
0,1,0,0,-2.8,0,GO:0071698,olfactory placode development,M010,1,0
1,0,0,-2.2,0,0,R-HSA-1810476,RIP-mediated NFkB activation via ZBP1,M100,1,0
0,0,1,0,0,-3.6,WP5224,2q37 copy number variation syndrome,M001,1,0
1,0,0,-3.9,0,0,R-HSA-9006931,Signaling by Nuclear Receptors,M100,1,0
1,0,0,-2.2,0,0,GO:0010565,regulation of cellular ketone metabolic process,M100,1,0
0,1,0,0,-2.4,0,WP22,IL 9 signaling pathway,M010,1,0
0,1,0,0,-3,0,GO:0048534,hematopoietic or lymphoid organ development,M010,1,0
0,1,0,0,-3,0,R-HSA-5683057,MAPK family signaling cascades,M010,1,0
0,1,0,0,-2.7,0,R-HSA-8939236,RUNX1 regulates transcription of genes involved in differentiation of HSCs,M010,1,0
1,0,0,-2.6,0,0,M15,PID LYSOPHOSPHOLIPID PATHWAY,M100,1,0
0,1,0,0,-3,0,GO:0050808,synapse organization,M010,1,0
1,0,0,-2.5,0,0,R-HSA-3232118,SUMOylation of transcription factors,M100,1,0
0,1,0,0,-2.3,0,WP4191,Caloric restriction and aging,M010,1,0
0,1,0,0,-2.4,0,GO:1902284,neuron projection extension involved in neuron projection guidance,M010,1,0
1,0,0,-2.5,0,0,WP5174,Ulcerative colitis signaling,M100,1,0
1,0,0,-2.6,0,0,GO:0043087,regulation of GTPase activity,M100,1,0
0,1,0,0,-3.6,0,R-HSA-9607240,FLT3 Signaling,M010,1,0
1,0,0,-2.5,0,0,GO:0002705,positive regulation of leukocyte mediated immunity,M100,1,0
0,0,1,0,0,-4.2,R-HSA-2029482,Regulation of actin dynamics for phagocytic cup formation,M001,1,0
0,1,0,0,-2.4,0,GO:0002063,chondrocyte development,M010,1,0
1,0,0,-3.2,0,0,GO:0007224,smoothened signaling pathway,M100,1,0
1,0,0,-3.2,0,0,GO:0010817,regulation of hormone levels,M100,1,0
0,1,0,0,-2.6,0,R-HSA-5653656,Vesicle-mediated transport,M010,1,0
1,0,0,-2.8,0,0,GO:0021546,rhombomere development,M100,1,0
1,0,0,-2.8,0,0,R-HSA-5603029,IkBA variant leads to EDA-ID,M100,1,0
1,0,0,-2.2,0,0,GO:2000739,regulation of mesenchymal stem cell differentiation,M100,1,0
0,0,1,0,0,-2.6,GO:0050775,positive regulation of dendrite morphogenesis,M001,1,0
0,0,1,0,0,-2.7,GO:1902106,negative regulation of leukocyte differentiation,M001,1,0
1,0,0,-2.3,0,0,GO:0043401,steroid hormone mediated signaling pathway,M100,1,0
1,0,0,-2,0,0,GO:0072210,metanephric nephron development,M100,1,0
0,0,1,0,0,-3.4,GO:2000107,negative regulation of leukocyte apoptotic process,M001,1,0
1,0,0,-2.2,0,0,GO:0070666,regulation of mast cell proliferation,M100,1,0
1,0,0,-2.5,0,0,GO:0010922,positive regulation of phosphatase activity,M100,1,0
0,1,0,0,-3.5,0,GO:0071696,ectodermal placode development,M010,1,0
1,0,0,-4,0,0,GO:0003231,cardiac ventricle development,M100,1,0
0,0,1,0,0,-3.9,R-HSA-2029481,FCGR activation,M001,1,0
0,1,0,0,-3.1,0,R-HSA-8939902,Regulation of RUNX2 expression and activity,M010,1,0
0,1,0,0,-2.3,0,GO:0002886,regulation of myeloid leukocyte mediated immunity,M010,1,0
0,1,0,0,-2.1,0,GO:0003071,renal system process involved in regulation of systemic arterial blood pressure,M010,1,0
0,1,0,0,-2.5,0,GO:0007159,leukocyte cell-cell adhesion,M010,1,0
1,0,0,-2.4,0,0,WP4685,Melanoma,M100,1,0
1,0,0,-2.4,0,0,hsa05216,Thyroid cancer,M100,1,0
1,0,0,-2.4,0,0,GO:0061333,renal tubule morphogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0032808,lacrimal gland development,M100,1,0
0,1,0,0,-3.1,0,R-HSA-6798695,Neutrophil degranulation,M010,1,0
1,0,0,-2.8,0,0,GO:0030210,heparin biosynthetic process,M100,1,0
1,0,0,-2,0,0,R-HSA-1912422,Pre-NOTCH Expression and Processing,M100,1,0
0,0,1,0,0,-2.3,GO:0032642,regulation of chemokine production,M001,1,0
0,1,0,0,-2.6,0,GO:0032715,negative regulation of interleukin-6 production,M010,1,0
1,0,0,-2.8,0,0,WP5322,CKAP4 signaling pathway map,M100,1,0
1,0,0,-2.5,0,0,R-HSA-975155,MyD88 dependent cascade initiated on endosome,M100,1,0
1,0,0,-4.2,0,0,GO:0048608,reproductive structure development,M100,1,0
1,0,0,-3,0,0,GO:0010596,negative regulation of endothelial cell migration,M100,1,0
0,0,1,0,0,-4.1,M141,PID PI3KCI PATHWAY,M001,1,0
1,0,0,-2.2,0,0,GO:0007221,positive regulation of transcription of Notch receptor target,M100,1,0
0,0,1,0,0,-3.5,hsa05142,Chagas disease,M001,1,0
0,0,1,0,0,-2.6,GO:0072126,positive regulation of glomerular mesangial cell proliferation,M001,1,0
1,0,0,-2.4,0,0,GO:0061036,positive regulation of cartilage development,M100,1,0
1,0,0,-4.4,0,0,GO:0007548,sex differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0032651,regulation of interleukin-1 beta production,M100,1,0
1,0,0,-2.2,0,0,R-HSA-975138,TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation,M100,1,0
1,0,0,-3.2,0,0,R-HSA-1592230,Mitochondrial biogenesis,M100,1,0
1,0,0,-2,0,0,GO:0046889,positive regulation of lipid biosynthetic process,M100,1,0
0,1,0,0,-2.2,0,hsa04612,Antigen processing and presentation,M010,1,0
0,1,0,0,-3.8,0,GO:0007215,glutamate receptor signaling pathway,M010,1,0
0,1,0,0,-2.3,0,GO:0043254,regulation of protein-containing complex assembly,M010,1,0
1,0,0,-2.2,0,0,WP4269,Ethanol metabolism production of ROS by CYP2E1,M100,1,0
1,0,0,-2.3,0,0,WP1991,SRF and miRs in smooth muscle differentiation and proliferation,M100,1,0
0,1,0,0,-3.1,0,GO:0007268,chemical synaptic transmission,M010,1,0
1,0,0,-2.1,0,0,WP3927,BMP signaling in eyelid development,M100,1,0
1,0,0,-2.2,0,0,GO:0021903,rostrocaudal neural tube patterning,M100,1,0
1,0,0,-2.4,0,0,GO:1901201,regulation of extracellular matrix assembly,M100,1,0
1,0,0,-5.2,0,0,GO:1902894,negative regulation of miRNA transcription,M100,1,0
1,0,0,-3.4,0,0,GO:0043410,positive regulation of MAPK cascade,M100,1,0
1,0,0,-2.8,0,0,GO:0010614,negative regulation of cardiac muscle hypertrophy,M100,1,0
1,0,0,-3.8,0,0,R-HSA-5619507,Activation of HOX genes during differentiation,M100,1,0
1,0,0,-3,0,0,WP4746,Thyroid hormones production and peripheral downstream signaling effects,M100,1,0
0,0,1,0,0,-2.9,GO:0038093,Fc receptor signaling pathway,M001,1,0
1,0,0,-2.3,0,0,GO:0097720,calcineurin-mediated signaling,M100,1,0
0,1,0,0,-3.4,0,GO:1990868,response to chemokine,M010,1,0
0,0,1,0,0,-6.2,R-HSA-9664407,Parasite infection,M001,1,0
1,0,0,-3.3,0,0,GO:0045137,development of primary sexual characteristics,M100,1,0
1,0,0,-3.4,0,0,GO:2000047,regulation of cell-cell adhesion mediated by cadherin,M100,1,0
0,1,0,0,-2.1,0,M285,PID HNF3A PATHWAY,M010,1,0
0,1,0,0,-2.1,0,GO:0010575,positive regulation of vascular endothelial growth factor production,M010,1,0
0,1,0,0,-3.5,0,R-HSA-202430,Translocation of ZAP-70 to Immunological synapse,M010,1,0
0,1,0,0,-2.4,0,GO:0032695,negative regulation of interleukin-12 production,M010,1,0
1,0,0,-2.8,0,0,GO:0003223,ventricular compact myocardium morphogenesis,M100,1,0
1,0,0,-3.3,0,0,GO:0045860,positive regulation of protein kinase activity,M100,1,0
0,1,0,0,-2.3,0,GO:1902255,positive regulation of intrinsic apoptotic signaling pathway by p53 class mediator,M010,1,0
0,1,0,0,-2.3,0,hsa05131,Shigellosis,M010,1,0
1,0,0,-2.1,0,0,GO:0001678,intracellular glucose homeostasis,M100,1,0
0,1,0,0,-3.2,0,GO:0043304,regulation of mast cell degranulation,M010,1,0
0,1,0,0,-2.2,0,GO:0001961,positive regulation of cytokine-mediated signaling pathway,M010,1,0
0,0,1,0,0,-2.7,WP4312,Rett syndrome causing genes,M001,1,0
1,0,0,-2.1,0,0,WP722,Serotonin HTR1 group and FOS pathway,M100,1,0
1,0,0,-2.1,0,0,GO:1905332,positive regulation of morphogenesis of an epithelium,M100,1,0
1,0,0,-2.4,0,0,GO:0006024,glycosaminoglycan biosynthetic process,M100,1,0
1,0,0,-2.7,0,0,GO:0003222,ventricular trabecula myocardium morphogenesis,M100,1,0
1,0,0,-2.2,0,0,GO:0090184,positive regulation of kidney development,M100,1,0
0,1,0,0,-2.3,0,R-HSA-9664873,Pexophagy,M010,1,0
0,1,0,0,-2.1,0,GO:0040020,regulation of meiotic nuclear division,M010,1,0
1,0,0,-3,0,0,R-HSA-8939211,ESR-mediated signaling,M100,1,0
0,1,0,0,-2.2,0,GO:0030219,megakaryocyte differentiation,M010,1,0
0,1,0,0,-2.5,0,WP4949,16p11 2 proximal deletion syndrome,M010,1,0
1,0,0,-2.7,0,0,GO:2000136,regulation of cell proliferation involved in heart morphogenesis,M100,1,0
0,1,0,0,-2.6,0,GO:0045446,endothelial cell differentiation,M010,1,0
0,1,0,0,-2.8,0,GO:0060686,negative regulation of prostatic bud formation,M010,1,0
1,0,0,-2.2,0,0,GO:0001714,endodermal cell fate specification,M100,1,0
1,0,0,-2.6,0,0,WP3640,Imatinib and chronic myeloid leukemia,M100,1,0
1,0,0,-2.1,0,0,R-HSA-9758919,Epithelial-Mesenchymal Transition (EMT) during gastrulation,M100,1,0
1,0,0,-4.1,0,0,GO:0060412,ventricular septum morphogenesis,M100,1,0
1,0,0,-2.5,0,0,GO:0046661,male sex differentiation,M100,1,0
0,0,1,0,0,-2.7,GO:0045061,thymic T cell selection,M001,1,0
1,0,0,-2.8,0,0,GO:0051347,positive regulation of transferase activity,M100,1,0
1,0,0,-2.9,0,0,GO:0060396,growth hormone receptor signaling pathway,M100,1,0
0,0,1,0,0,-3.6,R-HSA-9725371,Nuclear events stimulated by ALK signaling in cancer,M001,1,0
1,0,0,-2.7,0,0,GO:0062013,positive regulation of small molecule metabolic process,M100,1,0
0,1,0,0,-2.3,0,GO:0043255,regulation of carbohydrate biosynthetic process,M010,1,0
0,0,1,0,0,-4.6,GO:0098543,detection of other organism,M001,1,0
1,0,0,-4.1,0,0,GO:0060324,face development,M100,1,0
0,1,0,0,-2.3,0,GO:0048537,mucosa-associated lymphoid tissue development,M010,1,0
0,1,0,0,-2.1,0,GO:0060576,intestinal epithelial cell development,M010,1,0
0,1,0,0,-2.2,0,GO:0060421,positive regulation of heart growth,M010,1,0
1,0,0,-3.3,0,0,WP4223,Ras signaling,M100,1,0
1,0,0,-2.8,0,0,GO:0016331,morphogenesis of embryonic epithelium,M100,1,0
1,0,0,-2.5,0,0,GO:0030316,osteoclast differentiation,M100,1,0
0,1,0,0,-2.9,0,hsa04912,GnRH signaling pathway,M010,1,0
0,1,0,0,-2.4,0,GO:0090497,mesenchymal cell migration,M010,1,0
0,1,0,0,-2.4,0,GO:0007350,blastoderm segmentation,M010,1,0
0,1,0,0,-3.6,0,M165,PID SYNDECAN 4 PATHWAY,M010,1,0
1,0,0,-2.1,0,0,GO:0030031,cell projection assembly,M100,1,0
1,0,0,-4.1,0,0,WP2880,Glucocorticoid receptor pathway,M100,1,0
0,1,0,0,-2.4,0,GO:0120035,regulation of plasma membrane bounded cell projection organization,M010,1,0
1,0,0,-2.7,0,0,GO:0003170,heart valve development,M100,1,0
1,0,0,-2.4,0,0,GO:0006022,aminoglycan metabolic process,M100,1,0
0,1,0,0,-4.4,0,WP3678,Amplification and expansion of oncogenic pathways as metastatic traits,M010,1,0
1,0,0,-2.6,0,0,hsa04710,Circadian rhythm,M100,1,0
0,1,0,0,-3.5,0,GO:0042509,regulation of tyrosine phosphorylation of STAT protein,M010,1,0
0,1,0,0,-2.1,0,R-HSA-111885,Opioid Signalling,M010,1,0
0,1,0,0,-6.9,0,GO:0000902,cell morphogenesis,M010,1,0
0,0,1,0,0,-4,hsa04666,Fc gamma R-mediated phagocytosis,M001,1,0
0,1,0,0,-2.2,0,GO:0031342,negative regulation of cell killing,M010,1,0
1,0,0,-3.2,0,0,GO:0034198,cellular response to amino acid starvation,M100,1,0
0,1,0,0,-2.5,0,GO:0060099,"regulation of phagocytosis, engulfment",M010,1,0
1,0,0,-2.1,0,0,GO:0021960,anterior commissure morphogenesis,M100,1,0
0,1,0,0,-2.5,0,GO:0050886,endocrine process,M010,1,0
0,1,0,0,-2.3,0,GO:0006898,receptor-mediated endocytosis,M010,1,0
1,0,0,-2.7,0,0,WP4658,Small cell lung cancer,M100,1,0
0,0,1,0,0,-2.1,GO:0045600,positive regulation of fat cell differentiation,M001,1,0
1,0,0,-2.2,0,0,GO:0051091,positive regulation of DNA-binding transcription factor activity,M100,1,0
0,1,0,0,-2.3,0,GO:1902683,regulation of receptor localization to synapse,M010,1,0
1,0,0,-4.6,0,0,R-HSA-3108232,SUMO E3 ligases SUMOylate target proteins,M100,1,0
0,1,0,0,-2.3,0,GO:0070229,negative regulation of lymphocyte apoptotic process,M010,1,0
1,0,0,-2.1,0,0,R-HSA-442720,CREB1 phosphorylation through the activation of Adenylate Cyclase,M100,1,0
1,0,0,-2.3,0,0,hsa04148,Efferocytosis,M100,1,0
0,1,0,0,-2.3,0,R-HSA-9020558,Interleukin-2 signaling,M010,1,0
0,0,1,0,0,-2.3,GO:0060135,maternal process involved in female pregnancy,M001,1,0
1,0,0,-2.2,0,0,GO:0014887,cardiac muscle adaptation,M100,1,0
1,0,0,-2,0,0,R-HSA-450294,MAP kinase activation,M100,1,0
0,1,0,0,-2.5,0,GO:0044344,cellular response to fibroblast growth factor stimulus,M010,1,0
0,1,0,0,-2.1,0,GO:0050921,positive regulation of chemotaxis,M010,1,0
0,0,1,0,0,-2.7,WP3858,Toll like receptor signaling related to MyD88,M001,1,0
1,0,0,-2.8,0,0,hsa05220,Chronic myeloid leukemia,M100,1,0
1,0,0,-2.4,0,0,GO:0003177,pulmonary valve development,M100,1,0
0,0,1,0,0,-2.1,GO:0048935,peripheral nervous system neuron development,M001,1,0
0,1,0,0,-2.1,0,GO:0010518,positive regulation of phospholipase activity,M010,1,0
1,0,0,-2,0,0,GO:0061384,heart trabecula morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0048644,muscle organ morphogenesis,M100,1,0
0,1,0,0,-2.7,0,WP3947,Serotonin and anxiety,M010,1,0
0,0,1,0,0,-2.3,R-HSA-8951936,RUNX3 regulates p14-ARF,M001,1,0
1,0,0,-2.5,0,0,hsa04015,Rap1 signaling pathway,M100,1,0
1,0,0,-2.1,0,0,GO:0015014,"heparan sulfate proteoglycan biosynthetic process, polysaccharide chain biosynthetic process",M100,1,0
1,0,0,-2.8,0,0,GO:0051170,import into nucleus,M100,1,0
1,0,0,-2.3,0,0,WP5216,Warburg effect modulated by deubiquitinating enzymes and their substrates,M100,1,0
1,0,0,-2.2,0,0,GO:1900037,regulation of cellular response to hypoxia,M100,1,0
1,0,0,-3.1,0,0,GO:0045332,phospholipid translocation,M100,1,0
0,0,1,0,0,-2.3,GO:0045638,negative regulation of myeloid cell differentiation,M001,1,0
0,0,1,0,0,-3.9,hsa04650,Natural killer cell mediated cytotoxicity,M001,1,0
0,1,0,0,-2.2,0,GO:1903034,regulation of response to wounding,M010,1,0
1,0,0,-3.4,0,0,CORUM:5193,"TNF-alpha/NF-kappa B signaling complex (CHUK, KPNA3, NFKB2, NFKBIB, REL, IKBKG,  NFKB1, NFKBIE, RELB,  NFKBIA, RELA, TNIP2)",M100,1,0
0,1,0,0,-2.1,0,GO:0007406,negative regulation of neuroblast proliferation,M010,1,0
1,0,0,-2.3,0,0,R-HSA-416482,G alpha (12/13) signalling events,M100,1,0
0,0,1,0,0,-2.4,GO:0060998,regulation of dendritic spine development,M001,1,0
1,0,0,-3.6,0,0,GO:0060438,trachea development,M100,1,0
1,0,0,-2.3,0,0,GO:0042402,cellular biogenic amine catabolic process,M100,1,0
1,0,0,-4.8,0,0,WP4331,Neovascularisation processes,M100,1,0
0,1,0,0,-2.1,0,WP4300,Extracellular vesicles in the crosstalk of cardiac cells,M010,1,0
0,1,0,0,-2.5,0,GO:0003197,endocardial cushion development,M010,1,0
0,1,0,0,-2.8,0,GO:0055059,asymmetric neuroblast division,M010,1,0
0,1,0,0,-2.8,0,GO:0002076,osteoblast development,M010,1,0
1,0,0,-3.4,0,0,M37,PID NFKAPPAB CANONICAL PATHWAY,M100,1,0
0,1,0,0,-3.2,0,GO:0030866,cortical actin cytoskeleton organization,M010,1,0
0,0,1,0,0,-2.4,WP5072,Modulators of TCR signaling and T cell activation,M001,1,0
1,0,0,-2.1,0,0,GO:0060045,positive regulation of cardiac muscle cell proliferation,M100,1,0
1,0,0,-4.3,0,0,WP289,Myometrial relaxation and contraction pathways,M100,1,0
0,1,0,0,-2.1,0,GO:1901798,positive regulation of signal transduction by p53 class mediator,M010,1,0
1,0,0,-2.3,0,0,GO:0001655,urogenital system development,M100,1,0
1,0,0,-2.4,0,0,hsa05206,MicroRNAs in cancer,M100,1,0
1,0,0,-3.8,0,0,GO:0050777,negative regulation of immune response,M100,1,0
1,0,0,-2.2,0,0,GO:0001937,negative regulation of endothelial cell proliferation,M100,1,0
1,0,0,-3.8,0,0,WP2911,miRNA targets in ECM and membrane receptors,M100,1,0
0,1,0,0,-3,0,WP3893,Development and heterogeneity of the ILC family,M010,1,0
0,1,0,0,-4.8,0,GO:0032989,cellular anatomical entity morphogenesis,M010,1,0
1,0,0,-2.1,0,0,R-HSA-168164,Toll Like Receptor 3 (TLR3) Cascade,M100,1,0
1,0,0,-2.2,0,0,R-HSA-166016,Toll Like Receptor 4 (TLR4) Cascade,M100,1,0
0,0,1,0,0,-2.8,GO:0060249,anatomical structure homeostasis,M001,1,0
0,1,0,0,-2.8,0,CORUM:1519,IL6ST-PRKCD-STAT3 complex,M010,1,0
0,1,0,0,-2.6,0,GO:0071622,regulation of granulocyte chemotaxis,M010,1,0
1,0,0,-3,0,0,GO:0003208,cardiac ventricle morphogenesis,M100,1,0
0,1,0,0,-2.3,0,GO:0060685,regulation of prostatic bud formation,M010,1,0
1,0,0,-2.6,0,0,GO:0048592,eye morphogenesis,M100,1,0
1,0,0,-4.7,0,0,GO:0062009,secondary palate development,M100,1,0
1,0,0,-2.8,0,0,WP4263,Pancreatic adenocarcinoma pathway,M100,1,0
1,0,0,-4.3,0,0,GO:0060350,endochondral bone morphogenesis,M100,1,0
0,1,0,0,-2.1,0,GO:0097306,cellular response to alcohol,M010,1,0
1,0,0,-2.2,0,0,CORUM:3045,hs4 enhancer complex (faster migrating complex),M100,1,0
1,0,0,-3.1,0,0,GO:0006953,acute-phase response,M100,1,0
0,0,1,0,0,-2.1,R-HSA-2029485,Role of phospholipids in phagocytosis,M001,1,0
1,0,0,-2.2,0,0,GO:0022028,tangential migration from the subventricular zone to the olfactory bulb,M100,1,0
0,0,1,0,0,-5,R-HSA-2029480,Fcgamma receptor (FCGR) dependent phagocytosis,M001,1,0
1,0,0,-3.2,0,0,GO:0050873,brown fat cell differentiation,M100,1,0
0,1,0,0,-2.4,0,GO:0048846,axon extension involved in axon guidance,M010,1,0
0,1,0,0,-2.3,0,GO:0060214,endocardium formation,M010,1,0
0,1,0,0,-2.4,0,R-HSA-73980,RNA Polymerase III Transcription Termination,M010,1,0
1,0,0,-3.5,0,0,GO:0045923,positive regulation of fatty acid metabolic process,M100,1,0
1,0,0,-4.4,0,0,GO:0048511,rhythmic process,M100,1,0
1,0,0,-2,0,0,GO:0030890,positive regulation of B cell proliferation,M100,1,0
1,0,0,-2.8,0,0,GO:0048752,semicircular canal morphogenesis,M100,1,0
0,0,1,0,0,-2.6,GO:0032688,negative regulation of interferon-beta production,M001,1,0
0,1,0,0,-2.3,0,R-HSA-372708,p130Cas linkage to MAPK signaling for integrins,M010,1,0
0,0,1,0,0,-2.3,GO:0032103,positive regulation of response to external stimulus,M001,1,0
0,0,1,0,0,-2.8,GO:0001894,tissue homeostasis,M001,1,0
1,0,0,-2.1,0,0,GO:0048146,positive regulation of fibroblast proliferation,M100,1,0
0,1,0,0,-2.7,0,GO:0002887,negative regulation of myeloid leukocyte mediated immunity,M010,1,0
1,0,0,-3.2,0,0,GO:0008406,gonad development,M100,1,0
1,0,0,-2,0,0,GO:0043124,negative regulation of canonical NF-kappaB signal transduction,M100,1,0
0,0,1,0,0,-2.1,GO:0008589,regulation of smoothened signaling pathway,M001,1,0
1,0,0,-2.1,0,0,GO:0003309,type B pancreatic cell differentiation,M100,1,0
1,0,0,-2.5,0,0,hsa05418,Fluid shear stress and atherosclerosis,M100,1,0
0,1,0,0,-5.6,0,GO:0048812,neuron projection morphogenesis,M010,1,0
0,0,1,0,0,-2.5,WP399,Wnt signaling pathway and pluripotency,M001,1,0
0,1,0,0,-2.1,0,GO:0030595,leukocyte chemotaxis,M010,1,0
1,0,0,-3.5,0,0,GO:0090009,primitive streak formation,M100,1,0
0,0,1,0,0,-2.1,GO:1901989,positive regulation of cell cycle phase transition,M001,1,0
1,0,0,-2.2,0,0,GO:0098773,skin epidermis development,M100,1,0
1,0,0,-4.1,0,0,GO:0061008,hepaticobiliary system development,M100,1,0
1,0,0,-4.4,0,0,GO:2000181,negative regulation of blood vessel morphogenesis,M100,1,0
1,0,0,-2.4,0,0,GO:0120161,regulation of cold-induced thermogenesis,M100,1,0
0,0,1,0,0,-3,R-HSA-8935964,RUNX1 regulates expression of components of tight junctions,M001,1,0
0,1,0,0,-2.4,0,hsa04145,Phagosome,M010,1,0
0,0,1,0,0,-2.1,R-HSA-4420097,VEGFA-VEGFR2 Pathway,M001,1,0
0,1,0,0,-2,0,GO:0008217,regulation of blood pressure,M010,1,0
1,0,0,-4.2,0,0,CORUM:5233,TNF-alpha/NF-kappa B signaling complex 5,M100,1,0
1,0,0,-2.1,0,0,GO:0002825,regulation of T-helper 1 type immune response,M100,1,0
1,0,0,-3.6,0,0,GO:0001816,cytokine production,M100,1,0
0,1,0,0,-3.5,0,R-HSA-76009,Platelet Aggregation (Plug Formation),M010,1,0
0,1,0,0,-2.8,0,GO:0002399,MHC class II protein complex assembly,M010,1,0
1,0,0,-3.7,0,0,WP4239,Epithelial to mesenchymal transition in colorectal cancer,M100,1,0
0,1,0,0,-2.1,0,R-HSA-2644606,Constitutive Signaling by NOTCH1 PEST Domain Mutants,M010,1,0
1,0,0,-2.8,0,0,GO:0060420,regulation of heart growth,M100,1,0
0,1,0,0,-2.5,0,GO:0050804,modulation of chemical synaptic transmission,M010,1,0
0,1,0,0,-2.4,0,R-HSA-6783589,Interleukin-6 family signaling,M010,1,0
1,0,0,-2.1,0,0,GO:0007605,sensory perception of sound,M100,1,0
1,0,0,-2.1,0,0,CORUM:5735,TGF-beta receptor-SMAD3 complex,M100,1,0
1,0,0,-2.2,0,0,GO:0003176,aortic valve development,M100,1,0
0,1,0,0,-2.1,0,R-HSA-9669938,Signaling by KIT in disease,M010,1,0
0,1,0,0,-3.6,0,GO:0045598,regulation of fat cell differentiation,M010,1,0
1,0,0,-2,0,0,GO:0072088,nephron epithelium morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0090189,regulation of branching involved in ureteric bud morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0043500,muscle adaptation,M100,1,0
0,1,0,0,-2.1,0,GO:0051961,negative regulation of nervous system development,M010,1,0
0,1,0,0,-2.1,0,hsa04150,mTOR signaling pathway,M010,1,0
0,1,0,0,-2.8,0,GO:0002318,myeloid progenitor cell differentiation,M010,1,0
1,0,0,-3,0,0,GO:0035051,cardiocyte differentiation,M100,1,0
1,0,0,-2.1,0,0,R-HSA-2025928,Calcineurin activates NFAT,M100,1,0
1,0,0,-5,0,0,GO:0002068,glandular epithelial cell development,M100,1,0
0,1,0,0,-3.5,0,GO:0099536,synaptic signaling,M010,1,0
0,1,0,0,-3.8,0,GO:0061551,trigeminal ganglion development,M010,1,0
1,0,0,-2.6,0,0,R-HSA-201722,Formation of the beta-catenin:TCF transactivating complex,M100,1,0
0,0,1,0,0,-2.6,R-HSA-2730905,Role of LAT2/NTAL/LAB on calcium mobilization,M001,1,0
0,1,0,0,-2.5,0,hsa04940,Type I diabetes mellitus,M010,1,0
1,0,0,-3.5,0,0,GO:0060534,trachea cartilage development,M100,1,0
1,0,0,-2.5,0,0,GO:0071229,cellular response to acid chemical,M100,1,0
0,0,1,0,0,-2.7,GO:0071364,cellular response to epidermal growth factor stimulus,M001,1,0
0,0,1,0,0,-2.6,GO:0010770,positive regulation of cell morphogenesis,M001,1,0
1,0,0,-2.8,0,0,WP195,IL 1 signaling pathway,M100,1,0
1,0,0,-2.8,0,0,GO:0032909,regulation of transforming growth factor beta2 production,M100,1,0
1,0,0,-2.1,0,0,GO:0036438,maintenance of lens transparency,M100,1,0
0,1,0,0,-2.2,0,R-HSA-2132295,MHC class II antigen presentation,M010,1,0
1,0,0,-2.6,0,0,GO:0048593,camera-type eye morphogenesis,M100,1,0
0,0,1,0,0,-2.3,R-HSA-164952,The role of Nef in HIV-1 replication and disease pathogenesis,M001,1,0
0,1,0,0,-2.1,0,GO:0032940,secretion by cell,M010,1,0
1,0,0,-4.3,0,0,WP5236,Markers of kidney cell lineage,M100,1,0
0,1,0,0,-3.1,0,GO:0010975,regulation of neuron projection development,M010,1,0
0,0,1,0,0,-2.5,M71,PID ILK PATHWAY,M001,1,0
1,0,0,-4.5,0,0,GO:0060972,left/right pattern formation,M100,1,0
0,1,0,0,-2.7,0,R-HSA-9012852,Signaling by NOTCH3,M010,1,0
0,0,1,0,0,-2.1,GO:0061744,motor behavior,M001,1,0
1,0,0,-2.4,0,0,GO:0006023,aminoglycan biosynthetic process,M100,1,0
0,0,1,0,0,-2.2,WP560,TGF beta receptor signaling,M001,1,0
0,1,0,0,-5.1,0,R-HSA-202427,Phosphorylation of CD3 and TCR zeta chains,M010,1,0
1,0,0,-2.9,0,0,GO:0055021,regulation of cardiac muscle tissue growth,M100,1,0
0,0,1,0,0,-2.4,GO:0030852,regulation of granulocyte differentiation,M001,1,0
1,0,0,-5.2,0,0,GO:0010562,positive regulation of phosphorus metabolic process,M100,1,0
0,1,0,0,-2.1,0,GO:0043301,negative regulation of leukocyte degranulation,M010,1,0
0,0,1,0,0,-2.1,hsa04611,Platelet activation,M001,1,0
1,0,0,-2,0,0,GO:0032147,activation of protein kinase activity,M100,1,0
0,0,1,0,0,-2.4,GO:0042129,regulation of T cell proliferation,M001,1,0
0,1,0,0,-2.1,0,GO:0010837,regulation of keratinocyte proliferation,M010,1,0
0,0,1,0,0,-3,R-HSA-8941333,RUNX2 regulates genes involved in differentiation of myeloid cells,M001,1,0
0,0,1,0,0,-3.4,R-HSA-9006335,Signaling by Erythropoietin,M001,1,0
0,0,1,0,0,-3.2,GO:0021544,subpallium development,M001,1,0
1,0,0,-3.2,0,0,GO:1990823,response to leukemia inhibitory factor,M100,1,0
1,0,0,-2.2,0,0,WP4538,Regulatory circuits of the STAT3 signaling pathway,M100,1,0
1,0,0,-2.8,0,0,R-HSA-9018519,Estrogen-dependent gene expression,M100,1,0
0,1,0,0,-2.1,0,GO:1990138,neuron projection extension,M010,1,0
0,1,0,0,-2.6,0,GO:0006109,regulation of carbohydrate metabolic process,M010,1,0
1,0,0,-2.1,0,0,GO:0051058,negative regulation of small GTPase mediated signal transduction,M100,1,0
1,0,0,-2.2,0,0,hsa04810,Regulation of actin cytoskeleton,M100,1,0
0,1,0,0,-3.8,0,GO:1905331,negative regulation of morphogenesis of an epithelium,M010,1,0
0,1,0,0,-2.4,0,hsa05330,Allograft rejection,M010,1,0
0,0,1,0,0,-2.5,GO:0045089,positive regulation of innate immune response,M001,1,0
0,1,0,0,-5.5,0,GO:0120039,plasma membrane bounded cell projection morphogenesis,M010,1,0
0,1,0,0,-2.2,0,WP4534,Mechanoregulation and pathology of YAP TAZ via Hippo and non Hippo mechanisms,M010,1,0
0,0,1,0,0,-3,GO:0038001,paracrine signaling,M001,1,0
1,0,0,-4.3,0,0,R-HSA-9707616,Heme signaling,M100,1,0
0,1,0,0,-2.1,0,GO:0035329,hippo signaling,M010,1,0
0,1,0,0,-2.8,0,GO:0001959,regulation of cytokine-mediated signaling pathway,M010,1,0
0,0,1,0,0,-2.6,hsa05145,Toxoplasmosis,M001,1,0
0,1,0,0,-2.1,0,WP4537,Hippo YAP signaling,M010,1,0
1,0,0,-2.4,0,0,R-HSA-9660821,ADORA2B mediated anti-inflammatory cytokines production,M100,1,0
0,1,0,0,-2.1,0,GO:0031623,receptor internalization,M010,1,0
1,0,0,-3.8,0,0,hsa05160,Hepatitis C,M100,1,0
1,0,0,-2.1,0,0,GO:0060674,placenta blood vessel development,M100,1,0
0,1,0,0,-3.6,0,GO:0014032,neural crest cell development,M010,1,0
0,1,0,0,-4.4,0,GO:0048667,cell morphogenesis involved in neuron differentiation,M010,1,0
1,0,0,-3.8,0,0,GO:0046620,regulation of organ growth,M100,1,0
0,0,1,0,0,-2.3,GO:0030854,positive regulation of granulocyte differentiation,M001,1,0
0,1,0,0,-3.5,0,R-HSA-9706369,Negative regulation of FLT3,M010,1,0
0,1,0,0,-2.1,0,GO:0010560,positive regulation of glycoprotein biosynthetic process,M010,1,0
0,0,1,0,0,-2.3,R-HSA-8940973,RUNX2 regulates osteoblast differentiation,M001,1,0
0,1,0,0,-2.3,0,GO:0046425,regulation of receptor signaling pathway via JAK-STAT,M010,1,0
1,0,0,-2.5,0,0,GO:0002700,regulation of production of molecular mediator of immune response,M100,1,0
0,0,1,0,0,-3.9,GO:0050773,regulation of dendrite development,M001,1,0
0,1,0,0,-2.2,0,GO:0060428,lung epithelium development,M010,1,0
0,1,0,0,-2.3,0,GO:0016049,cell growth,M010,1,0
0,1,0,0,-2.3,0,R-HSA-948021,Transport to the Golgi and subsequent modification,M010,1,0
0,1,0,0,-2.8,0,GO:0031331,positive regulation of cellular catabolic process,M010,1,0
0,1,0,0,-2.1,0,R-HSA-6807004,Negative regulation of MET activity,M010,1,0
0,1,0,0,-2.1,0,GO:0032743,positive regulation of interleukin-2 production,M010,1,0
1,0,0,-2.4,0,0,GO:0071634,regulation of transforming growth factor beta production,M100,1,0
1,0,0,-2.1,0,0,GO:0010921,regulation of phosphatase activity,M100,1,0
1,0,0,-2.3,0,0,hsa05225,Hepatocellular carcinoma,M100,1,0
1,0,0,-2.6,0,0,GO:0014855,striated muscle cell proliferation,M100,1,0
1,0,0,-3.3,0,0,GO:0014741,negative regulation of muscle hypertrophy,M100,1,0
1,0,0,-2.2,0,0,GO:0097696,receptor signaling pathway via STAT,M100,1,0
1,0,0,-4.1,0,0,GO:0051897,positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M100,1,0
1,0,0,-2.3,0,0,GO:0001711,endodermal cell fate commitment,M100,1,0
1,0,0,-2.1,0,0,GO:0038086,VEGF-activated platelet-derived growth factor receptor signaling pathway,M100,1,0
0,0,1,0,0,-3.6,GO:0016045,detection of bacterium,M001,1,0
0,1,0,0,-2.4,0,GO:0010559,regulation of glycoprotein biosynthetic process,M010,1,0
1,0,0,-2.8,0,0,WP3407,FTO obesity variant mechanism,M100,1,0
0,0,1,0,0,-2.4,GO:0046636,negative regulation of alpha-beta T cell activation,M001,1,0
1,0,0,-2.6,0,0,GO:1901532,regulation of hematopoietic progenitor cell differentiation,M100,1,0
1,0,0,-2.1,0,0,GO:0032765,positive regulation of mast cell cytokine production,M100,1,0
0,1,0,0,-3.1,0,CORUM:725,P2X7 receptor signalling complex,M010,1,0
0,1,0,0,-2.7,0,GO:0045766,positive regulation of angiogenesis,M010,1,0
0,1,0,0,-2.2,0,GO:0051338,regulation of transferase activity,M010,1,0
1,0,0,-2.2,0,0,GO:0042092,type 2 immune response,M100,1,0
0,1,0,0,-3.5,0,M234,PID IL2 STAT5 PATHWAY,M010,1,0
1,0,0,-2,0,0,GO:0043535,regulation of blood vessel endothelial cell migration,M100,1,0
1,0,0,-2,0,0,GO:0032570,response to progesterone,M100,1,0
0,1,0,0,-2.6,0,GO:0001825,blastocyst formation,M010,1,0
1,0,0,-3.7,0,0,hsa04657,IL-17 signaling pathway,M100,1,0
0,1,0,0,-2.8,0,GO:0060788,ectodermal placode formation,M010,1,0
0,0,1,0,0,-2.4,WP4842,Mammalian disorder of sexual development,M001,1,0
1,0,0,-2.5,0,0,GO:0002532,production of molecular mediator involved in inflammatory response,M100,1,0
0,1,0,0,-2.1,0,R-HSA-9670439,"Signaling by phosphorylated juxtamembrane, extracellular and kinase domain KIT mutants",M010,1,0
0,0,1,0,0,-2.4,GO:0042100,B cell proliferation,M001,1,0
0,1,0,0,-2.3,0,GO:0006935,chemotaxis,M010,1,0
0,1,0,0,-2.7,0,GO:1905459,regulation of vascular associated smooth muscle cell apoptotic process,M010,1,0
1,0,0,-2.4,0,0,GO:0071496,cellular response to external stimulus,M100,1,0
0,0,1,0,0,-2.4,GO:0050890,cognition,M001,1,0
0,1,0,0,-2.8,0,GO:0030910,olfactory placode formation,M010,1,0
1,0,0,-2,0,0,GO:0072078,nephron tubule morphogenesis,M100,1,0
1,0,0,-6.7,0,0,GO:0003416,endochondral bone growth,M100,1,0
1,0,0,-3.5,0,0,GO:0043434,response to peptide hormone,M100,1,0
0,0,1,0,0,-4,GO:0038094,Fc-gamma receptor signaling pathway,M001,1,0
0,1,0,0,-2.7,0,GO:0099537,trans-synaptic signaling,M010,1,0
1,0,0,-2.2,0,0,GO:0001706,endoderm formation,M100,1,0
1,0,0,-3.6,0,0,GO:0060351,cartilage development involved in endochondral bone morphogenesis,M100,1,0
0,1,0,0,-2.4,0,GO:0099565,"chemical synaptic transmission, postsynaptic",M010,1,0
0,1,0,0,-2.8,0,GO:0097152,mesenchymal cell apoptotic process,M010,1,0
0,0,1,0,0,-3,R-HSA-109582,Hemostasis,M001,1,0
0,0,1,0,0,-2.6,GO:0072525,pyridine-containing compound biosynthetic process,M001,1,0
0,0,1,0,0,-4.1,GO:0032733,positive regulation of interleukin-10 production,M001,1,0
1,0,0,-2.8,0,0,GO:0043313,regulation of neutrophil degranulation,M100,1,0
1,0,0,-2.5,0,0,R-HSA-168181,Toll Like Receptor 7/8 (TLR7/8) Cascade,M100,1,0
0,0,1,0,0,-2.4,hsa04620,Toll-like receptor signaling pathway,M001,1,0
0,1,0,0,-2.6,0,GO:0048675,axon extension,M010,1,0
0,1,0,0,-2.5,0,GO:1905153,regulation of membrane invagination,M010,1,0
1,0,0,-3,0,0,GO:0030857,negative regulation of epithelial cell differentiation,M100,1,0
1,0,0,-3,0,0,GO:0072163,mesonephric epithelium development,M100,1,0
0,0,1,0,0,-3.2,WP75,Toll like receptor signaling pathway,M001,1,0
1,0,0,-2.4,0,0,GO:0009612,response to mechanical stimulus,M100,1,0
1,0,0,-3.7,0,0,WP5417,Cell lineage map for neuronal differentiation,M100,1,0
1,0,0,-2.2,0,0,GO:0002576,platelet degranulation,M100,1,0
0,1,0,0,-2.4,0,GO:0060839,endothelial cell fate commitment,M010,1,0
1,0,0,-3.1,0,0,GO:0062012,regulation of small molecule metabolic process,M100,1,0
0,1,0,0,-2.4,0,GO:0002495,antigen processing and presentation of peptide antigen via MHC class II,M010,1,0
1,0,0,-2.3,0,0,GO:0060947,cardiac vascular smooth muscle cell differentiation,M100,1,0
0,1,0,0,-3.1,0,GO:0061550,cranial ganglion development,M010,1,0
0,1,0,0,-3,0,GO:0001779,natural killer cell differentiation,M010,1,0
0,1,0,0,-2.3,0,GO:0050856,regulation of T cell receptor signaling pathway,M010,1,0
1,0,0,-3.4,0,0,R-HSA-9818749,Regulation of NFE2L2 gene expression,M100,1,0
0,1,0,0,-2.4,0,hsa04360,Axon guidance,M010,1,0
1,0,0,-3,0,0,GO:0060317,cardiac epithelial to mesenchymal transition,M100,1,0
0,0,1,0,0,-2.1,WP710,DNA damage response only ATM dependent,M001,1,0
1,0,0,-2.4,0,0,GO:0061326,renal tubule development,M100,1,0
1,0,0,-2.1,0,0,GO:1901256,regulation of macrophage colony-stimulating factor production,M100,1,0
1,0,0,-2.6,0,0,WP4496,Signal transduction through IL1R,M100,1,0
1,0,0,-2.3,0,0,GO:0007494,midgut development,M100,1,0
0,0,1,0,0,-4,GO:2000106,regulation of leukocyte apoptotic process,M001,1,0
1,0,0,-2.4,0,0,WP2870,Extracellular vesicle mediated signaling in recipient cells,M100,1,0
0,1,0,0,-2.3,0,GO:0032729,positive regulation of type II interferon production,M010,1,0
0,1,0,0,-2.1,0,R-HSA-5654726,Negative regulation of FGFR1 signaling,M010,1,0
0,0,1,0,0,-2.1,GO:0030032,lamellipodium assembly,M001,1,0
0,1,0,0,-2.3,0,GO:0072106,regulation of ureteric bud formation,M010,1,0
0,1,0,0,-2.1,0,GO:0060602,branch elongation of an epithelium,M010,1,0
0,1,0,0,-3.3,0,GO:0048639,positive regulation of developmental growth,M010,1,0
1,0,0,-3.7,0,0,R-HSA-9707564,Cytoprotection by HMOX1,M100,1,0
1,0,0,-5.2,0,0,GO:0045937,positive regulation of phosphate metabolic process,M100,1,0
0,1,0,0,-2.7,0,GO:0043409,negative regulation of MAPK cascade,M010,1,0
0,1,0,0,-2.2,0,GO:0032873,negative regulation of stress-activated MAPK cascade,M010,1,0
0,1,0,0,-3,0,GO:0003272,endocardial cushion formation,M010,1,0
1,0,0,-2.4,0,0,GO:0046847,filopodium assembly,M100,1,0
1,0,0,-2.7,0,0,CORUM:5232,"TNF-alpha/Nf-kappa B signaling complex (RPL6, RPL30, RPS13, CHUK, DDX3X, NFKB2, NFKBIB, REL, IKBKG, NFKB1, MAP3K8, RELB, GLG1, NFKBIA, RELA, TNIP2,  GTF2I)",M100,1,0
0,1,0,0,-2.2,0,WP4906,3q29 copy number variation syndrome,M010,1,0
1,0,0,-2.1,0,0,CORUM:1890,ELK1-SRF-ELK4 complex,M100,1,0
0,1,0,0,-2.3,0,GO:0035470,positive regulation of vascular wound healing,M010,1,0
0,0,1,0,0,-3,GO:1900017,positive regulation of cytokine production involved in inflammatory response,M001,1,0
0,1,0,0,-2.5,0,R-HSA-9634815,Transcriptional Regulation by NPAS4,M010,1,0
0,1,0,0,-2.3,0,GO:0061311,cell surface receptor signaling pathway involved in heart development,M010,1,0
1,0,0,-2.4,0,0,GO:0051150,regulation of smooth muscle cell differentiation,M100,1,0
0,0,1,0,0,-2.2,R-HSA-9679506,SARS-CoV Infections,M001,1,0
0,1,0,0,-2.4,0,R-HSA-446203,Asparagine N-linked glycosylation,M010,1,0
1,0,0,-3.7,0,0,GO:0090183,regulation of kidney development,M100,1,0
0,1,0,0,-4.6,0,GO:0031175,neuron projection development,M010,1,0
0,0,1,0,0,-2,GO:0006897,endocytosis,M001,1,0
1,0,0,-2.9,0,0,WP254,Apoptosis,M100,1,0
0,0,1,0,0,-3.5,R-HSA-164944,Nef and signal transduction,M001,1,0
1,0,0,-2.3,0,0,GO:0007492,endoderm development,M100,1,0
0,1,0,0,-4.1,0,GO:0003073,regulation of systemic arterial blood pressure,M010,1,0
0,1,0,0,-2.3,0,CORUM:2536,PLC-gamma-2-SLP-76-Lyn-Grb2 complex,M010,1,0
0,0,1,0,0,-2.4,GO:0031960,response to corticosteroid,M001,1,0
0,1,0,0,-3.8,0,GO:0042531,positive regulation of tyrosine phosphorylation of STAT protein,M010,1,0
0,1,0,0,-2.4,0,GO:0014823,response to activity,M010,1,0
0,1,0,0,-2.1,0,GO:0071222,cellular response to lipopolysaccharide,M010,1,0
1,0,0,-2.7,0,0,GO:0014743,regulation of muscle hypertrophy,M100,1,0
0,1,0,0,-3.1,0,GO:0044092,negative regulation of molecular function,M010,1,0
0,0,1,0,0,-2.1,GO:0043376,"regulation of CD8-positive, alpha-beta T cell differentiation",M001,1,0
0,1,0,0,-2.2,0,R-HSA-202424,Downstream TCR signaling,M010,1,0
1,0,0,-2,0,0,GO:0042789,mRNA transcription by RNA polymerase II,M100,1,0
1,0,0,-2.1,0,0,GO:0043200,response to amino acid,M100,1,0
0,1,0,0,-2.1,0,R-HSA-5684996,MAPK1/MAPK3 signaling,M010,1,0
1,0,0,-4.4,0,0,GO:1901343,negative regulation of vasculature development,M100,1,0
0,1,0,0,-2.4,0,GO:0034616,response to laminar fluid shear stress,M010,1,0
0,1,0,0,-2.8,0,GO:0099566,regulation of postsynaptic cytosolic calcium ion concentration,M010,1,0
0,1,0,0,-2,0,GO:0042391,regulation of membrane potential,M010,1,0
0,1,0,0,-2.3,0,GO:0051660,establishment of centrosome localization,M010,1,0
0,1,0,0,-2.1,0,GO:0046885,regulation of hormone biosynthetic process,M010,1,0
1,0,0,-3.3,0,0,GO:0051896,regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction,M100,1,0
1,0,0,-2.1,0,0,GO:0002822,regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains,M100,1,0
0,1,0,0,-2.2,0,GO:0140352,export from cell,M010,1,0
0,0,1,0,0,-3.2,GO:1904936,interneuron migration,M001,1,0
1,0,0,-3.5,0,0,GO:0033173,calcineurin-NFAT signaling cascade,M100,1,0
1,0,0,-3.4,0,0,GO:0071300,cellular response to retinoic acid,M100,1,0
0,1,0,0,-2.3,0,GO:0001707,mesoderm formation,M010,1,0
0,1,0,0,-3.1,0,GO:0003158,endothelium development,M010,1,0
1,0,0,-2.8,0,0,GO:0072012,glomerulus vasculature development,M100,1,0
0,1,0,0,-3,0,GO:0070588,calcium ion transmembrane transport,M010,1,0
1,0,0,-2.1,0,0,CORUM:5467,IKB(alpha)-RELA-cREL complex,M100,1,0
0,0,1,0,0,-6.2,R-HSA-9664417,Leishmania phagocytosis,M001,1,0
0,0,1,0,0,-2.6,WP4884,Pathogenesis of SARS CoV 2 mediated by nsp9 nsp10 complex,M001,1,0
0,1,0,0,-2.3,0,GO:0003093,regulation of glomerular filtration,M010,1,0
1,0,0,-3.2,0,0,GO:0014706,striated muscle tissue development,M100,1,0
0,1,0,0,-3.2,0,WP5284,Cell interactions of the pancreatic cancer microenvironment,M010,1,0
1,0,0,-2.3,0,0,R-HSA-168138,Toll Like Receptor 9 (TLR9) Cascade,M100,1,0
1,0,0,-2.5,0,0,WP384,Apoptosis modulation by HSP70,M100,1,0
0,1,0,0,-2.4,0,GO:0019886,antigen processing and presentation of exogenous peptide antigen via MHC class II,M010,1,0
0,0,1,0,0,-3.1,R-HSA-451927,Interleukin-2 family signaling,M001,1,0
0,1,0,0,-2.8,0,hsa05033,Nicotine addiction,M010,1,0
0,1,0,0,-2.2,0,GO:0050792,regulation of viral process,M010,1,0
1,0,0,-2.7,0,0,R-HSA-975871,MyD88 cascade initiated on plasma membrane,M100,1,0
1,0,0,-2.1,0,0,GO:0003430,growth plate cartilage chondrocyte growth,M100,1,0
1,0,0,-3.5,0,0,GO:0038095,Fc-epsilon receptor signaling pathway,M100,1,0
1,0,0,-2.7,0,0,R-HSA-9679191,Potential therapeutics for SARS,M100,1,0
0,1,0,0,-2.1,0,GO:0007163,establishment or maintenance of cell polarity,M010,1,0
0,1,0,0,-2.5,0,GO:0099177,regulation of trans-synaptic signaling,M010,1,0
1,0,0,-2.3,0,0,GO:0072080,nephron tubule development,M100,1,0
0,0,1,0,0,-2.5,M175,PID ERBB2 ERBB3 PATHWAY,M001,1,0
0,0,1,0,0,-2.7,WP3888,VEGFA VEGFR2 signaling,M001,1,0
0,0,1,0,0,-3.1,GO:1903707,negative regulation of hemopoiesis,M001,1,0
1,0,0,-2.1,0,0,M12,PID RHOA PATHWAY,M100,1,0
0,1,0,0,-3.2,0,WP4336,ncRNAs involved in Wnt signaling in hepatocellular carcinoma,M010,1,0
0,1,0,0,-2.8,0,R-HSA-9680350,Signaling by CSF1 (M-CSF) in myeloid cells,M010,1,0
0,1,0,0,-2.1,0,GO:0097150,neuronal stem cell population maintenance,M010,1,0
1,0,0,-3.1,0,0,GO:0006305,DNA alkylation,M100,1,0
0,1,0,0,-2.7,0,GO:0045070,positive regulation of viral genome replication,M010,1,0
0,1,0,0,-2.7,0,GO:0019932,second-messenger-mediated signaling,M010,1,0
1,0,0,-2.2,0,0,GO:0014898,cardiac muscle hypertrophy in response to stress,M100,1,0
1,0,0,-2.1,0,0,WP4480,Altered glycosylation of MUC1 in tumor microenvironment,M100,1,0
1,0,0,-2.7,0,0,GO:0030540,female genitalia development,M100,1,0
1,0,0,-2.3,0,0,GO:0090130,tissue migration,M100,1,0
0,0,1,0,0,-2.7,M34,PID TCR PATHWAY,M001,1,0
0,1,0,0,-4.7,0,GO:0007409,axonogenesis,M010,1,0
1,0,0,-2.3,0,0,GO:0008584,male gonad development,M100,1,0
1,0,0,-2.1,0,0,GO:0035148,tube formation,M100,1,0
1,0,0,-2.2,0,0,GO:0070166,enamel mineralization,M100,1,0
0,1,0,0,-2.7,0,GO:0034121,regulation of toll-like receptor signaling pathway,M010,1,0
0,1,0,0,-3.8,0,GO:1902473,regulation of protein localization to synapse,M010,1,0
1,0,0,-4.1,0,0,GO:0007368,determination of left/right symmetry,M100,1,0
1,0,0,-2.1,0,0,GO:0035306,positive regulation of dephosphorylation,M100,1,0
0,1,0,0,-2.8,0,GO:0098926,postsynaptic signal transduction,M010,1,0
1,0,0,-2.1,0,0,GO:0003407,neural retina development,M100,1,0
1,0,0,-2,0,0,hsa05134,Legionellosis,M100,1,0
1,0,0,-2.4,0,0,GO:0060612,adipose tissue development,M100,1,0
0,1,0,0,-2.1,0,R-HSA-389948,PD-1 signaling,M010,1,0
1,0,0,-3.4,0,0,GO:0051145,smooth muscle cell differentiation,M100,1,0
1,0,0,-3.1,0,0,GO:0010002,cardioblast differentiation,M100,1,0
0,1,0,0,-2.7,0,R-HSA-1295596,Spry regulation of FGF signaling,M010,1,0
0,1,0,0,-2,0,GO:0033673,negative regulation of kinase activity,M010,1,0
1,0,0,-2.2,0,0,GO:0010573,vascular endothelial growth factor production,M100,1,0
1,0,0,-4.1,0,0,GO:0003417,growth plate cartilage development,M100,1,0
0,1,0,0,-2.3,0,GO:0030902,hindbrain development,M010,1,0
0,0,1,0,0,-2.6,R-HSA-1266695,Interleukin-7 signaling,M001,1,0
0,1,0,0,-2.7,0,GO:0051783,regulation of nuclear division,M010,1,0
1,0,0,-2.4,0,0,GO:0060038,cardiac muscle cell proliferation,M100,1,0
1,0,0,-3.8,0,0,WP1591,Heart development,M100,1,0
1,0,0,-2.1,0,0,WP3617,Photodynamic therapy induced NF kB survival signaling,M100,1,0
0,0,1,0,0,-2.8,hsa05130,Pathogenic Escherichia coli infection,M001,1,0
0,1,0,0,-3,0,GO:0045197,establishment or maintenance of epithelial cell apical/basal polarity,M010,1,0
1,0,0,-2.1,0,0,GO:0048818,positive regulation of hair follicle maturation,M100,1,0
1,0,0,-2.4,0,0,WP1541,Energy metabolism,M100,1,0
1,0,0,-7.1,0,0,WP5144,NRP1 triggered signaling pathways in pancreatic cancer,M100,1,0
1,0,0,-2.7,0,0,hsa04350,TGF-beta signaling pathway,M100,1,0
0,0,1,0,0,-3.3,GO:0031349,positive regulation of defense response,M001,1,0
0,1,0,0,-2.4,0,GO:0010508,positive regulation of autophagy,M010,1,0
1,0,0,-4.1,0,0,GO:0061458,reproductive system development,M100,1,0
1,0,0,-2.7,0,0,GO:0001666,response to hypoxia,M100,1,0
1,0,0,-2.6,0,0,GO:0001942,hair follicle development,M100,1,0
1,0,0,-2.8,0,0,WP5202,Alstrom syndrome,M100,1,0
1,0,0,-2.8,0,0,GO:0060043,regulation of cardiac muscle cell proliferation,M100,1,0
1,0,0,-2.1,0,0,GO:0060486,club cell differentiation,M100,1,0
0,1,0,0,-2.3,0,R-HSA-6806834,Signaling by MET,M010,1,0
1,0,0,-2.1,0,0,M270,PID MAPK TRK PATHWAY,M100,1,0
0,1,0,0,-2.3,0,GO:0032350,regulation of hormone metabolic process,M010,1,0
1,0,0,-2.6,0,0,GO:0010453,regulation of cell fate commitment,M100,1,0
1,0,0,-3.9,0,0,GO:0009799,specification of symmetry,M100,1,0
1,0,0,-2.4,0,0,hsa04014,Ras signaling pathway,M100,1,0
0,1,0,0,-2.1,0,GO:0097066,response to thyroid hormone,M010,1,0
0,1,0,0,-2.1,0,GO:0032673,regulation of interleukin-4 production,M010,1,0
0,0,1,0,0,-3,R-HSA-8939246,RUNX1 regulates transcription of genes involved in differentiation of myeloid cells,M001,1,0
1,0,0,-2.2,0,0,WP516,Hypertrophy model,M100,1,0
0,1,0,0,-4,0,R-HSA-354192,Integrin signaling,M010,1,0
1,0,0,-2.1,0,0,GO:0010458,exit from mitosis,M100,1,0
0,1,0,0,-2.5,0,GO:0002396,MHC protein complex assembly,M010,1,0
1,0,0,-2.8,0,0,R-HSA-5607763,CLEC7A (Dectin-1) induces NFAT activation,M100,1,0
0,1,0,0,-2.7,0,GO:0045936,negative regulation of phosphate metabolic process,M010,1,0
0,1,0,0,-2.2,0,GO:0070232,regulation of T cell apoptotic process,M010,1,0
1,0,0,-3.4,0,0,M145,PID P53 DOWNSTREAM PATHWAY,M100,1,0
1,0,0,-2.3,0,0,GO:0043030,regulation of macrophage activation,M100,1,0
0,1,0,0,-2.4,0,GO:0070243,regulation of thymocyte apoptotic process,M010,1,0
1,0,0,-3.2,0,0,GO:0033674,positive regulation of kinase activity,M100,1,0
0,1,0,0,-2.1,0,M8,PID ENDOTHELIN PATHWAY,M010,1,0
0,1,0,0,-2.1,0,WP5362,TAR syndrome,M010,1,0
0,1,0,0,-2.7,0,GO:0032680,regulation of tumor necrosis factor production,M010,1,0
0,1,0,0,-2.5,0,GO:0007200,phospholipase C-activating G protein-coupled receptor signaling pathway,M010,1,0
1,0,0,-3.5,0,0,GO:0045601,regulation of endothelial cell differentiation,M100,1,0
0,1,0,0,-2.1,0,GO:0051099,positive regulation of binding,M010,1,0
1,0,0,-2.8,0,0,R-HSA-1912408,Pre-NOTCH Transcription and Translation,M100,1,0
1,0,0,-2.2,0,0,WP304,Kit receptor signaling pathway,M100,1,0
1,0,0,-2.4,0,0,M45,PID CD40 PATHWAY,M100,1,0
0,0,1,0,0,-2.5,GO:0097028,dendritic cell differentiation,M001,1,0
1,0,0,-2.8,0,0,R-HSA-8866911,TFAP2 (AP-2) family regulates transcription of cell cycle factors,M100,1,0
0,0,1,0,0,-2.6,hsa04934,Cushing syndrome,M001,1,0
1,0,0,-2.2,0,0,GO:0072171,mesonephric tubule morphogenesis,M100,1,0
0,1,0,0,-3.1,0,GO:0001829,trophectodermal cell differentiation,M010,1,0
0,1,0,0,-2.5,0,GO:0048524,positive regulation of viral process,M010,1,0
0,1,0,0,-2.3,0,GO:0097553,calcium ion transmembrane import into cytosol,M010,1,0
0,0,1,0,0,-2.6,GO:0050764,regulation of phagocytosis,M001,1,0
1,0,0,-2.8,0,0,GO:0035905,ascending aorta development,M100,1,0
0,1,0,0,-5.5,0,GO:0048858,cell projection morphogenesis,M010,1,0
1,0,0,-2.3,0,0,GO:0032259,methylation,M100,1,0
0,1,0,0,-2.1,0,GO:0048015,phosphatidylinositol-mediated signaling,M010,1,0
0,0,1,0,0,-3.2,GO:0043491,phosphatidylinositol 3-kinase/protein kinase B signal transduction,M001,1,0
1,0,0,-2.1,0,0,GO:0038091,positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway,M100,1,0
1,0,0,-3,0,0,R-HSA-2151201,Transcriptional activation of mitochondrial biogenesis,M100,1,0
0,1,0,0,-2.3,0,GO:0010533,regulation of activation of Janus kinase activity,M010,1,0
1,0,0,-2.9,0,0,R-HSA-8866910,TFAP2 (AP-2) family regulates transcription of growth factors and their receptors,M100,1,0
1,0,0,-2.3,0,0,GO:0198738,cell-cell signaling by wnt,M100,1,0
0,1,0,0,-2.7,0,R-HSA-112316,Neuronal System,M010,1,0
1,0,0,-2.6,0,0,GO:0043534,blood vessel endothelial cell migration,M100,1,0
1,0,0,-5.4,0,0,WP382,MAPK signaling pathway,M100,1,0
0,1,0,0,-2.1,0,R-HSA-1433559,Regulation of KIT signaling,M010,1,0
1,0,0,-4.3,0,0,GO:0035904,aorta development,M100,1,0
1,0,0,-2.2,0,0,GO:0071281,cellular response to iron ion,M100,1,0
1,0,0,-2.7,0,0,GO:0001823,mesonephros development,M100,1,0
1,0,0,-2.6,0,0,GO:0006606,protein import into nucleus,M100,1,0
1,0,0,-2.6,0,0,WP4830,GDNF RET signaling axis,M100,1,0
1,0,0,-2.2,0,0,GO:0003299,muscle hypertrophy in response to stress,M100,1,0
0,1,0,0,-2,0,GO:0060828,regulation of canonical Wnt signaling pathway,M010,1,0
0,1,0,0,-2.3,0,R-HSA-9768919,NPAS4 regulates expression of target genes,M010,1,0
0,1,0,0,-2.2,0,GO:0031329,regulation of cellular catabolic process,M010,1,0
1,0,0,-2.9,0,0,R-HSA-3214841,PKMTs methylate histone lysines,M100,1,0
0,1,0,0,-2.3,0,GO:0043305,negative regulation of mast cell degranulation,M010,1,0
0,1,0,0,-2.2,0,GO:0032649,regulation of type II interferon production,M010,1,0
1,0,0,-3.7,0,0,GO:0030278,regulation of ossification,M100,1,0
1,0,0,-2.9,0,0,GO:1990928,response to amino acid starvation,M100,1,0
0,1,0,0,-2.1,0,GO:0050858,negative regulation of antigen receptor-mediated signaling pathway,M010,1,0
1,0,0,-2.8,0,0,GO:0035910,ascending aorta morphogenesis,M100,1,0
0,1,0,0,-2.7,0,R-HSA-8866654,E3 ubiquitin ligases ubiquitinate target proteins,M010,1,0
0,1,0,0,-2.3,0,WP49,IL 2 signaling pathway,M010,1,0
1,0,0,-3,0,0,GO:0007179,transforming growth factor beta receptor signaling pathway,M100,1,0
0,1,0,0,-2.1,0,R-HSA-2644602,Signaling by NOTCH1 PEST Domain Mutants in Cancer,M010,1,0
0,1,0,0,-2.1,0,GO:0072148,epithelial cell fate commitment,M010,1,0
1,0,0,-2.2,0,0,CORUM:1372,Rb-tal-1-E2A-Lmo2-Ldb1 complex,M100,1,0
0,0,1,0,0,-2.1,GO:0042246,tissue regeneration,M001,1,0
0,1,0,0,-2.7,0,GO:0003160,endocardium morphogenesis,M010,1,0
1,0,0,-2.3,0,0,GO:0043502,regulation of muscle adaptation,M100,1,0
0,0,1,0,0,-2.9,GO:0009954,proximal/distal pattern formation,M001,1,0
1,0,0,-3.7,0,0,GO:0032526,response to retinoic acid,M100,1,0
0,1,0,0,-3.1,0,R-HSA-354194,GRB2:SOS provides linkage to MAPK signaling for Integrins,M010,1,0
1,0,0,-2.3,0,0,GO:0030500,regulation of bone mineralization,M100,1,0
1,0,0,-3.2,0,0,hsa04926,Relaxin signaling pathway,M100,1,0
0,0,1,0,0,-3.4,GO:0045577,regulation of B cell differentiation,M001,1,0
1,0,0,-2.9,0,0,WP4321,Thermogenesis,M100,1,0
1,0,0,-3,0,0,GO:0007623,circadian rhythm,M100,1,0
0,1,0,0,-2.1,0,GO:0021561,facial nerve development,M010,1,0
1,0,0,-2.7,0,0,GO:0045723,positive regulation of fatty acid biosynthetic process,M100,1,0
1,0,0,-2.8,0,0,CORUM:2086,NFKB1-NFKB2-RELA-RELB complex,M100,1,0
0,1,0,0,-2.4,0,GO:0090092,regulation of transmembrane receptor protein serine/threonine kinase signaling pathway,M010,1,0
0,0,1,0,0,-2.6,GO:0009611,response to wounding,M001,1,0
0,1,0,0,-2.4,0,R-HSA-204005,COPII-mediated vesicle transport,M010,1,0
0,1,0,0,-2.7,0,GO:0010563,negative regulation of phosphorus metabolic process,M010,1,0
1,0,0,-2.3,0,0,WP138,Androgen receptor signaling pathway,M100,1,0
0,1,0,0,-2.1,0,GO:0045859,regulation of protein kinase activity,M010,1,0
0,1,0,0,-2.1,0,WP2431,Spinal cord injury,M010,1,0
1,0,0,-4.1,0,0,GO:0035137,hindlimb morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0032872,regulation of stress-activated MAPK cascade,M100,1,0
0,0,1,0,0,-2.5,WP4217,Ebola virus infection in host,M001,1,0
0,1,0,0,-2.9,0,R-HSA-199991,Membrane Trafficking,M010,1,0
0,1,0,0,-2.2,0,GO:1903018,regulation of glycoprotein metabolic process,M010,1,0
0,0,1,0,0,-2.1,hsa04915,Estrogen signaling pathway,M001,1,0
0,1,0,0,-2.9,0,GO:0030510,regulation of BMP signaling pathway,M010,1,0
1,0,0,-2.1,0,0,GO:2000741,positive regulation of mesenchymal stem cell differentiation,M100,1,0
1,0,0,-2.8,0,0,WP2637,Interleukin 1 IL 1 structural pathway,M100,1,0
0,0,1,0,0,-4.4,M124,PID CXCR4 PATHWAY,M001,1,0
0,1,0,0,-2.1,0,GO:0019933,cAMP-mediated signaling,M010,1,0
1,0,0,-2.1,0,0,GO:0035879,plasma membrane lactate transport,M100,1,0
0,1,0,0,-2.4,0,GO:0070672,response to interleukin-15,M010,1,0
0,0,1,0,0,-4.2,GO:0032653,regulation of interleukin-10 production,M001,1,0
1,0,0,-3.5,0,0,CORUM:2084,NFKB1-NFKB2-REL-RELA-RELB complex,M100,1,0
0,1,0,0,-2.3,0,GO:0048588,developmental cell growth,M010,1,0
0,1,0,0,-2,0,GO:0043086,negative regulation of catalytic activity,M010,1,0
0,0,1,0,0,-2.6,GO:0019363,pyridine nucleotide biosynthetic process,M001,1,0
1,0,0,-2.9,0,0,hsa05222,Small cell lung cancer,M100,1,0
0,0,1,0,0,-3.4,GO:0098581,detection of external biotic stimulus,M001,1,0
1,0,0,-2.8,0,0,GO:0042692,muscle cell differentiation,M100,1,0
1,0,0,-2.4,0,0,GO:0070167,regulation of biomineral tissue development,M100,1,0
1,0,0,-2.4,0,0,GO:0070302,regulation of stress-activated protein kinase signaling cascade,M100,1,0
0,0,1,0,0,-2.1,M48,PID MET PATHWAY,M001,1,0
0,1,0,0,-3.5,0,R-HSA-2032785,YAP1- and WWTR1 (TAZ)-stimulated gene expression,M010,1,0
0,1,0,0,-2.3,0,GO:0071675,regulation of mononuclear cell migration,M010,1,0
0,1,0,0,-2.4,0,GO:0001755,neural crest cell migration,M010,1,0
1,0,0,-2.8,0,0,WP5397,Vitamin A1 and A5 X pathways,M100,1,0
0,1,0,0,-2.7,0,GO:0044057,regulation of system process,M010,1,0
0,1,0,0,-3,0,GO:1990806,ligand-gated ion channel signaling pathway,M010,1,0
1,0,0,-3.6,0,0,GO:0021545,cranial nerve development,M100,1,0
1,0,0,-2.2,0,0,GO:0015727,lactate transport,M100,1,0
1,0,0,-3,0,0,M115,PID REG GR PATHWAY,M100,1,0
1,0,0,-2.1,0,0,CORUM:6235,c-Fos-c-Jun-SAF-1 complex,M100,1,0
0,0,1,0,0,-2.6,GO:0009435,NAD biosynthetic process,M001,1,0
1,0,0,-2.1,0,0,GO:0003179,heart valve morphogenesis,M100,1,0
0,1,0,0,-2.3,0,GO:0045136,development of secondary sexual characteristics,M010,1,0
1,0,0,-2.1,0,0,GO:0060948,cardiac vascular smooth muscle cell development,M100,1,0
1,0,0,-2.6,0,0,GO:1990266,neutrophil migration,M100,1,0
1,0,0,-3.1,0,0,hsa05212,Pancreatic cancer,M100,1,0
1,0,0,-2.2,0,0,hsa04936,Alcoholic liver disease,M100,1,0
0,1,0,0,-2.3,0,GO:0042326,negative regulation of phosphorylation,M010,1,0
1,0,0,-2.3,0,0,GO:0016055,Wnt signaling pathway,M100,1,0
0,1,0,0,-2.3,0,GO:1990264,peptidyl-tyrosine dephosphorylation involved in inactivation of protein kinase activity,M010,1,0
0,1,0,0,-3.2,0,R-HSA-202433,Generation of second messenger molecules,M010,1,0
0,1,0,0,-2.3,0,GO:0070669,response to interleukin-2,M010,1,0
0,0,1,0,0,-2.4,GO:0043403,skeletal muscle tissue regeneration,M001,1,0
1,0,0,-2.2,0,0,GO:0007259,receptor signaling pathway via JAK-STAT,M100,1,0
1,0,0,-2.5,0,0,R-HSA-9827857,Specification of primordial germ cells,M100,1,0
1,0,0,-2.1,0,0,CORUM:6299,ELK1-SAP1a-EWS-FLI-FLI complex,M100,1,0
1,0,0,-2.9,0,0,GO:0033500,carbohydrate homeostasis,M100,1,0
0,1,0,0,-2.1,0,WP3931,Embryonic stem cell pluripotency pathways,M010,1,0
1,0,0,-2.9,0,0,hsa05165,Human papillomavirus infection,M100,1,0
0,1,0,0,-2.2,0,hsa05332,Graft-versus-host disease,M010,1,0
0,1,0,0,-3.1,0,GO:0030101,natural killer cell activation,M010,1,0
0,1,0,0,-2.1,0,GO:1902742,apoptotic process involved in development,M010,1,0
0,1,0,0,-2.4,0,GO:0008356,asymmetric cell division,M010,1,0
1,0,0,-2.1,0,0,WP536,Calcium regulation in cardiac cells,M100,1,0
0,0,1,0,0,-2.8,GO:0014902,myotube differentiation,M001,1,0
1,0,0,-3.8,0,0,GO:0001889,liver development,M100,1,0
1,0,0,-2.1,0,0,GO:0030203,glycosaminoglycan metabolic process,M100,1,0
0,1,0,0,-3.7,0,GO:0060384,innervation,M010,1,0
1,0,0,-3.5,0,0,GO:0048806,genitalia development,M100,1,0
1,0,0,-5.1,0,0,GO:0051056,regulation of small GTPase mediated signal transduction,M100,1,0
1,0,0,-2.2,0,0,WP1455,Serotonin transporter activity,M100,1,0
0,1,0,0,-2.5,0,GO:0035088,establishment or maintenance of apical/basal cell polarity,M010,1,0
0,1,0,0,-3.5,0,GO:1901722,regulation of cell proliferation involved in kidney development,M010,1,0
0,1,0,0,-2.6,0,GO:0050730,regulation of peptidyl-tyrosine phosphorylation,M010,1,0
0,0,1,0,0,-3,WP4582,Cancer immunotherapy by CTLA4 blockade,M001,1,0
1,0,0,-3.9,0,0,WP5353,A network map of Macrophage stimulating protein MSP signaling,M100,1,0
1,0,0,-3.8,0,0,GO:0014015,positive regulation of gliogenesis,M100,1,0
1,0,0,-2.6,0,0,GO:0048546,digestive tract morphogenesis,M100,1,0
0,1,0,0,-2.1,0,R-HSA-177929,Signaling by EGFR,M010,1,0
0,1,0,0,-3.4,0,GO:0043388,positive regulation of DNA binding,M010,1,0
0,1,0,0,-2.8,0,GO:1901741,positive regulation of myoblast fusion,M010,1,0
1,0,0,-2.2,0,0,M162,PID RXR VDR PATHWAY,M100,1,0
0,1,0,0,-2.7,0,GO:0034122,negative regulation of toll-like receptor signaling pathway,M010,1,0
0,1,0,0,-3.1,0,GO:0098916,anterograde trans-synaptic signaling,M010,1,0
0,1,0,0,-2.8,0,GO:0071699,olfactory placode morphogenesis,M010,1,0
1,0,0,-4.5,0,0,GO:0035116,embryonic hindlimb morphogenesis,M100,1,0
1,0,0,-2.8,0,0,GO:0060982,coronary artery morphogenesis,M100,1,0
1,0,0,-3.3,0,0,GO:0032922,circadian regulation of gene expression,M100,1,0
0,1,0,0,-2.2,0,GO:0030513,positive regulation of BMP signaling pathway,M010,1,0
0,1,0,0,-2.3,0,WP5398,NRXN1 deletion syndrome,M010,1,0
0,1,0,0,-2.3,0,R-HSA-9706377,FLT3 signaling by CBL mutants,M010,1,0
1,0,0,-2.8,0,0,WP4562,Canonical NF kB pathway,M100,1,0
0,1,0,0,-2.2,0,GO:0019884,antigen processing and presentation of exogenous antigen,M010,1,0
1,0,0,-6,0,0,GO:0098868,bone growth,M100,1,0
0,1,0,0,-2.1,0,R-HSA-1433557,Signaling by SCF-KIT,M010,1,0
0,0,1,0,0,-3,GO:0030222,eosinophil differentiation,M001,1,0
0,1,0,0,-4.8,0,GO:0007411,axon guidance,M010,1,0
1,0,0,-2,0,0,GO:0031668,cellular response to extracellular stimulus,M100,1,0
0,0,1,0,0,-2.5,GO:0043068,positive regulation of programmed cell death,M001,1,0
0,1,0,0,-2.5,0,hsa05310,Asthma,M010,1,0
1,0,0,-2.2,0,0,GO:0090132,epithelium migration,M100,1,0
1,0,0,-3,0,0,M65,PID FRA PATHWAY,M100,1,0
1,0,0,-3.9,0,0,WP3594,Circadian rhythm genes,M100,1,0
0,0,1,0,0,-3.5,R-HSA-8939247,RUNX1 regulates transcription of genes involved in interleukin signaling,M001,1,0
0,1,0,0,-2.3,0,GO:0010517,regulation of phospholipase activity,M010,1,0
1,0,0,-4.6,0,0,R-HSA-2990846,SUMOylation,M100,1,0
1,0,0,-3.7,0,0,GO:0051402,neuron apoptotic process,M100,1,0
0,1,0,0,-2.4,0,GO:0008015,blood circulation,M010,1,0
1,0,0,-4.5,0,0,GO:0035270,endocrine system development,M100,1,0
1,0,0,-2.3,0,0,GO:0002320,lymphoid progenitor cell differentiation,M100,1,0
1,0,0,-2.2,0,0,GO:0030593,neutrophil chemotaxis,M100,1,0
0,1,0,0,-2.5,0,GO:0001933,negative regulation of protein phosphorylation,M010,1,0
0,1,0,0,-2.3,0,GO:0031344,regulation of cell projection organization,M010,1,0
1,0,0,-2.2,0,0,WP4919,Neuroinflammation,M100,1,0
1,0,0,-2.8,0,0,GO:0034204,lipid translocation,M100,1,0
1,0,0,-4.3,0,0,GO:0050680,negative regulation of epithelial cell proliferation,M100,1,0
0,1,0,0,-2.5,0,GO:0002501,peptide antigen assembly with MHC protein complex,M010,1,0
0,0,1,0,0,-2.4,GO:0002431,Fc receptor mediated stimulatory signaling pathway,M001,1,0
1,0,0,-3.2,0,0,GO:0006959,humoral immune response,M100,1,0
1,0,0,-2.1,0,0,R-HSA-1852241,Organelle biogenesis and maintenance,M100,1,0
0,0,1,0,0,-2.3,GO:1903557,positive regulation of tumor necrosis factor superfamily cytokine production,M001,1,0
1,0,0,-2.1,0,0,hsa04022,cGMP-PKG signaling pathway,M100,1,0
1,0,0,-2.8,0,0,GO:2001222,regulation of neuron migration,M100,1,0
1,0,0,-4.1,0,0,GO:0003281,ventricular septum development,M100,1,0
0,1,0,0,-3.2,0,GO:0010463,mesenchymal cell proliferation,M010,1,0
1,0,0,-3,0,0,GO:0010633,negative regulation of epithelial cell migration,M100,1,0
0,1,0,0,-2.2,0,GO:0010595,positive regulation of endothelial cell migration,M010,1,0
0,1,0,0,-3.9,0,GO:0035235,ionotropic glutamate receptor signaling pathway,M010,1,0
1,0,0,-6.9,0,0,WP4674,Head and neck squamous cell carcinoma,M100,1,0
0,0,1,0,0,-2.6,R-HSA-8877330,RUNX1 and FOXP3 control the development of regulatory T lymphocytes (Tregs),M001,1,0
1,0,0,-2.8,0,0,GO:2000048,negative regulation of cell-cell adhesion mediated by cadherin,M100,1,0
1,0,0,-2.1,0,0,WP5395,Glycosaminoglycan synthesis in fibroblasts,M100,1,0
0,1,0,0,-3.1,0,WP4141,PI3K AKT mTOR vitamin D3 signaling,M010,1,0
1,0,0,-2.3,0,0,GO:0010631,epithelial cell migration,M100,1,0
0,1,0,0,-2.5,0,WP2873,Aryl hydrocarbon receptor pathway,M010,1,0
0,0,1,0,0,-2.3,GO:0014016,neuroblast differentiation,M001,1,0
1,0,0,-3.8,0,0,GO:0035265,organ growth,M100,1,0
1,0,0,-2.8,0,0,WP231,TNF alpha signaling pathway,M100,1,0
1,0,0,-2.4,0,0,GO:1905314,semi-lunar valve development,M100,1,0
1,0,0,-3,0,0,GO:0072164,mesonephric tubule development,M100,1,0
0,1,0,0,-2.7,0,R-HSA-9637628,Modulation by Mtb of host immune system,M010,1,0
1,0,0,-5.4,0,0,GO:0048384,retinoic acid receptor signaling pathway,M100,1,0
0,1,0,0,-2.7,0,GO:0045647,negative regulation of erythrocyte differentiation,M010,1,0
0,0,1,0,0,-2.4,GO:0046639,negative regulation of alpha-beta T cell differentiation,M001,1,0
1,0,0,-2.4,0,0,GO:0038061,non-canonical NF-kappaB signal transduction,M100,1,0
0,1,0,0,-2.3,0,CORUM:1054,ESR1-RELA-BCL3-NCOA3 complex,M010,1,0
0,1,0,0,-2.2,0,GO:0048538,thymus development,M010,1,0
0,0,1,0,0,-2.2,R-HSA-525793,Myogenesis,M001,1,0
0,1,0,0,-2.1,0,R-HSA-2894858,Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer,M010,1,0
0,0,1,0,0,-2.6,GO:0045088,regulation of innate immune response,M001,1,0
1,0,0,-2.7,0,0,hsa04371,Apelin signaling pathway,M100,1,0
1,0,0,-2.5,0,0,GO:0032330,regulation of chondrocyte differentiation,M100,1,0
1,0,0,-2.1,0,0,WP3413,NOTCH1 regulation of endothelial cell calcification,M100,1,0
0,1,0,0,-2.6,0,GO:1903555,regulation of tumor necrosis factor superfamily cytokine production,M010,1,0
0,1,0,0,-2.5,0,WP4698,Vitamin D sensitive calcium signaling in depression,M010,1,0
1,0,0,-2.6,0,0,GO:0045581,negative regulation of T cell differentiation,M100,1,0
1,0,0,-3.2,0,0,GO:0060977,coronary vasculature morphogenesis,M100,1,0
0,1,0,0,-2.3,0,R-HSA-1839124,FGFR1 mutant receptor activation,M010,1,0
0,1,0,0,-2.8,0,GO:0070099,regulation of chemokine-mediated signaling pathway,M010,1,0
0,1,0,0,-2.4,0,R-HSA-8983432,Interleukin-15 signaling,M010,1,0
0,1,0,0,-2.7,0,GO:0048340,paraxial mesoderm morphogenesis,M010,1,0
0,1,0,0,-2.3,0,GO:0042330,taxis,M010,1,0
0,0,1,0,0,-3.2,GO:0033077,T cell differentiation in thymus,M001,1,0
0,1,0,0,-2.4,0,GO:0001911,negative regulation of leukocyte mediated cytotoxicity,M010,1,0
1,0,0,-3.2,0,0,R-HSA-9013148,CDC42 GTPase cycle,M100,1,0
1,0,0,-2.8,0,0,GO:0060509,type I pneumocyte differentiation,M100,1,0
0,1,0,0,-2.7,0,GO:0043408,regulation of MAPK cascade,M010,1,0
0,1,0,0,-2.2,0,R-HSA-1236394,Signaling by ERBB4,M010,1,0
0,1,0,0,-3.1,0,R-HSA-9708530,Regulation of BACH1 activity,M010,1,0
1,0,0,-2.5,0,0,R-HSA-8980692,RHOA GTPase cycle,M100,1,0
0,1,0,0,-2.3,0,GO:0060713,labyrinthine layer morphogenesis,M010,1,0
0,0,1,0,0,-2.4,GO:0002862,negative regulation of inflammatory response to antigenic stimulus,M001,1,0
1,0,0,-2.4,0,0,hsa04392,Hippo signaling pathway - multiple species,M100,1,0
1,0,0,-4.5,0,0,GO:0048645,animal organ formation,M100,1,0
0,1,0,0,-2.3,0,GO:0098815,modulation of excitatory postsynaptic potential,M010,1,0
0,0,1,0,0,-2.2,R-HSA-6783783,Interleukin-10 signaling,M001,1,0
1,0,0,-3.5,0,0,GO:0060914,heart formation,M100,1,0
0,1,0,0,-2.1,0,GO:0051282,regulation of sequestering of calcium ion,M010,1,0
1,0,0,-2.1,0,0,GO:0009913,epidermal cell differentiation,M100,1,0
0,0,1,0,0,-2.3,GO:0010976,positive regulation of neuron projection development,M001,1,0
0,1,0,0,-2.1,0,R-HSA-2644603,Signaling by NOTCH1 in Cancer,M010,1,0
0,1,0,0,-2.8,0,GO:0021502,neural fold elevation formation,M010,1,0
0,1,0,0,-2.5,0,GO:0061245,establishment or maintenance of bipolar cell polarity,M010,1,0
1,0,0,-2.4,0,0,GO:0002718,regulation of cytokine production involved in immune response,M100,1,0
0,1,0,0,-2.5,0,GO:0006816,calcium ion transport,M010,1,0
1,0,0,-2.1,0,0,CORUM:5492,IKBA-p50-p65 Nf(kappa)B complex,M100,1,0
0,1,0,0,-3,0,GO:1901222,regulation of non-canonical NF-kappaB signal transduction,M010,1,0
0,1,0,0,-2.3,0,GO:0034392,negative regulation of smooth muscle cell apoptotic process,M010,1,0
0,1,0,0,-2.1,0,hsa05205,Proteoglycans in cancer,M010,1,0
1,0,0,-2.9,0,0,GO:0042593,glucose homeostasis,M100,1,0
1,0,0,-2.8,0,0,GO:1990830,cellular response to leukemia inhibitory factor,M100,1,0
0,1,0,0,-3.4,0,GO:1990869,cellular response to chemokine,M010,1,0
1,0,0,-2.1,0,0,GO:0110024,positive regulation of cardiac muscle myoblast proliferation,M100,1,0
0,0,1,0,0,-2.5,GO:0015908,fatty acid transport,M001,1,0
0,1,0,0,-2.8,0,GO:0071697,ectodermal placode morphogenesis,M010,1,0
0,1,0,0,-2.1,0,GO:0021610,facial nerve morphogenesis,M010,1,0
0,1,0,0,-2.1,0,GO:0003013,circulatory system process,M010,1,0
0,0,1,0,0,-2.6,GO:0019359,nicotinamide nucleotide biosynthetic process,M001,1,0
0,1,0,0,-3.1,0,R-HSA-112314,Neurotransmitter receptors and postsynaptic signal transmission,M010,1,0
0,0,1,0,0,-2.1,GO:0046641,positive regulation of alpha-beta T cell proliferation,M001,1,0
1,0,0,-2.3,0,0,GO:0002702,positive regulation of production of molecular mediator of immune response,M100,1,0
0,1,0,0,-4.1,0,hsa04390,Hippo signaling pathway,M010,1,0
1,0,0,-2.4,0,0,WP4018,Clear cell renal cell carcinoma pathways,M100,1,0
1,0,0,-2.2,0,0,WP61,Notch signaling pathway,M100,1,0
0,1,0,0,-2.3,0,R-HSA-5655302,Signaling by FGFR1 in disease,M010,1,0
0,0,1,0,0,-6.2,R-HSA-9664422,FCGR3A-mediated phagocytosis,M001,1,0
0,1,0,0,-2.4,0,R-HSA-877300,Interferon gamma signaling,M010,1,0
1,0,0,-2.6,0,0,GO:0097305,response to alcohol,M100,1,0
0,0,1,0,0,-2.5,hsa05231,Choline metabolism in cancer,M001,1,0
0,1,0,0,-2.2,0,GO:0042102,positive regulation of T cell proliferation,M010,1,0
0,1,0,0,-2.2,0,GO:0070303,negative regulation of stress-activated protein kinase signaling cascade,M010,1,0
1,0,0,-2.4,0,0,GO:0048566,embryonic digestive tract development,M100,1,0
1,0,0,-2.2,0,0,GO:0035873,lactate transmembrane transport,M100,1,0
1,0,0,-2.2,0,0,R-HSA-111931,PKA-mediated phosphorylation of CREB,M100,1,0
1,0,0,-2.8,0,0,GO:0060795,cell fate commitment involved in formation of primary germ layer,M100,1,0
0,0,1,0,0,-3.5,GO:1903845,negative regulation of cellular response to transforming growth factor beta stimulus,M001,1,0
0,1,0,0,-2,0,GO:0009101,glycoprotein biosynthetic process,M010,1,0
1,0,0,-2.4,0,0,GO:2000146,negative regulation of cell motility,M100,1,0
1,0,0,-2.2,0,0,R-HSA-3134963,DEx/H-box helicases activate type I IFN and inflammatory cytokines production,M100,1,0
0,1,0,0,-2,0,R-HSA-168898,Toll-like Receptor Cascades,M010,1,0
0,1,0,0,-4.8,0,GO:0035249,"synaptic transmission, glutamatergic",M010,1,0
1,0,0,-2.7,0,0,R-HSA-2219528,PI3K/AKT Signaling in Cancer,M100,1,0
1,0,0,-2.4,0,0,GO:0050673,epithelial cell proliferation,M100,1,0
0,0,1,0,0,-2.6,GO:2000516,"positive regulation of CD4-positive, alpha-beta T cell activation",M001,1,0
1,0,0,-2.7,0,0,WP5090,Complement system in neuronal development and plasticity,M100,1,0
0,1,0,0,-2.1,0,GO:1904893,negative regulation of receptor signaling pathway via STAT,M010,1,0
1,0,0,-2.3,0,0,hsa05226,Gastric cancer,M100,1,0
0,0,1,0,0,-2.5,GO:0090407,organophosphate biosynthetic process,M001,1,0
0,1,0,0,-2.8,0,GO:0002503,peptide antigen assembly with MHC class II protein complex,M010,1,0
1,0,0,-3.3,0,0,GO:0035883,enteroendocrine cell differentiation,M100,1,0
0,1,0,0,-2.4,0,R-HSA-3858494,Beta-catenin independent WNT signaling,M010,1,0
1,0,0,-2.1,0,0,GO:0048730,epidermis morphogenesis,M100,1,0
1,0,0,-4.1,0,0,R-HSA-1368108,"BMAL1:CLOCK,NPAS2 activates circadian gene expression",M100,1,0
0,1,0,0,-3.8,0,GO:0060710,chorio-allantoic fusion,M010,1,0
0,0,1,0,0,-4.2,GO:1900015,regulation of cytokine production involved in inflammatory response,M001,1,0
1,0,0,-2.1,0,0,GO:0090190,positive regulation of branching involved in ureteric bud morphogenesis,M100,1,0
1,0,0,-2.1,0,0,GO:0035283,central nervous system segmentation,M100,1,0
0,1,0,0,-2.1,0,R-HSA-2894862,Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants,M010,1,0
0,1,0,0,-2.4,0,R-HSA-5694530,Cargo concentration in the ER,M010,1,0
0,0,1,0,0,-2.7,hsa04725,Cholinergic synapse,M001,1,0
1,0,0,-2.7,0,0,GO:0060416,response to growth hormone,M100,1,0
1,0,0,-5.4,0,0,WP2435,Quercetin and Nf kB AP 1 induced apoptosis,M100,1,0
1,0,0,-2.4,0,0,GO:0045931,positive regulation of mitotic cell cycle,M100,1,0
1,0,0,-2.8,0,0,GO:0021891,olfactory bulb interneuron development,M100,1,0
1,0,0,-6.5,0,0,hsa05163,Human cytomegalovirus infection,M100,1,0
1,0,0,-2.6,0,0,M288,PID HES HEY PATHWAY,M100,1,0
1,0,0,-5.7,0,0,R-HSA-383280,Nuclear Receptor transcription pathway,M100,1,0
0,0,1,0,0,-2.6,R-HSA-9700645,ALK mutants bind TKIs,M001,1,0
0,1,0,0,-2.7,0,GO:0032088,negative regulation of NF-kappaB transcription factor activity,M010,1,0
1,0,0,-3,0,0,GO:0001657,ureteric bud development,M100,1,0
0,1,0,0,-2.3,0,R-HSA-9645135,STAT5 Activation,M010,1,0
0,0,1,0,0,-2.4,GO:0048665,neuron fate specification,M001,1,0
1,0,0,-2.6,0,0,hsa04714,Thermogenesis,M100,1,0
0,0,1,0,0,-2.1,GO:0006164,purine nucleotide biosynthetic process,M001,1,0
0,1,0,0,-2.1,0,R-HSA-6802948,Signaling by high-kinase activity BRAF mutants,M010,1,0
0,0,1,0,0,-2.1,GO:0072109,glomerular mesangium development,M001,1,0
1,0,0,-2.2,0,0,GO:0003418,growth plate cartilage chondrocyte differentiation,M100,1,0
1,0,0,-3.3,0,0,GO:0048738,cardiac muscle tissue development,M100,1,0
0,0,1,0,0,-2.7,GO:0038096,Fc-gamma receptor signaling pathway involved in phagocytosis,M001,1,0
1,0,0,-2.3,0,0,GO:0045834,positive regulation of lipid metabolic process,M100,1,0
1,0,0,-2.1,0,0,GO:0042752,regulation of circadian rhythm,M100,1,0
1,0,0,-2.1,0,0,hsa04933,AGE-RAGE signaling pathway in diabetic complications,M100,1,0
1,0,0,-2.4,0,0,WP4329,miRNA role in immune response in sepsis,M100,1,0
0,0,1,0,0,-2.6,R-HSA-8939245,RUNX1 regulates transcription of genes involved in BCR signaling,M001,1,0
0,1,0,0,-2.5,0,GO:1903035,negative regulation of response to wounding,M010,1,0
1,0,0,-2.9,0,0,GO:0071378,cellular response to growth hormone stimulus,M100,1,0
1,0,0,-2.3,0,0,GO:0010611,regulation of cardiac muscle hypertrophy,M100,1,0
0,1,0,0,-2.1,0,GO:0070102,interleukin-6-mediated signaling pathway,M010,1,0
0,0,1,0,0,-2.4,GO:0015909,long-chain fatty acid transport,M001,1,0
0,1,0,0,-2.4,0,GO:0098801,regulation of renal system process,M010,1,0
0,0,1,0,0,-3.3,GO:0070849,response to epidermal growth factor,M001,1,0
1,0,0,-4.4,0,0,GO:0016525,negative regulation of angiogenesis,M100,1,0
0,1,0,0,-2.5,0,GO:1904018,positive regulation of vasculature development,M010,1,0
0,0,1,0,0,-2.6,GO:0048857,neural nucleus development,M001,1,0
0,0,1,0,0,-2.1,M193,PID NEPHRIN NEPH1 PATHWAY,M001,1,0
0,0,1,0,0,-2.4,GO:0045655,regulation of monocyte differentiation,M001,1,0
0,1,0,0,-2.1,0,GO:0072539,T-helper 17 cell differentiation,M010,1,0
0,0,1,0,0,-3.5,GO:0050853,B cell receptor signaling pathway,M001,1,0
1,0,0,-2.4,0,0,GO:0097190,apoptotic signaling pathway,M100,1,0
0,0,1,0,0,-2.7,GO:0002433,immune response-regulating cell surface receptor signaling pathway involved in phagocytosis,M001,1,0
0,1,0,0,-2.5,0,GO:0071354,cellular response to interleukin-6,M010,1,0
0,1,0,0,-4.6,0,GO:0061564,axon development,M010,1,0
1,0,0,-3.5,0,0,GO:0031018,endocrine pancreas development,M100,1,0
1,0,0,-2.1,0,0,GO:0030858,positive regulation of epithelial cell differentiation,M100,1,0
0,0,1,0,0,-2.3,GO:0045661,regulation of myoblast differentiation,M001,1,0
0,1,0,0,-2.2,0,M3008,NABA ECM GLYCOPROTEINS,M010,1,0
1,0,0,-3.3,0,0,GO:0046660,female sex differentiation,M100,1,0
1,0,0,-3,0,0,hsa04932,Non-alcoholic fatty liver disease,M100,1,0
0,0,1,0,0,-2.3,GO:0009595,detection of biotic stimulus,M001,1,0
0,1,0,0,-2.4,0,GO:0002504,antigen processing and presentation of peptide or polysaccharide antigen via MHC class II,M010,1,0
0,1,0,0,-2.9,0,GO:0045599,negative regulation of fat cell differentiation,M010,1,0
0,0,1,0,0,-3.4,WP4565,Neural crest cell migration in cancer,M001,1,0
0,1,0,0,-2.3,0,GO:0034110,regulation of homotypic cell-cell adhesion,M010,1,0
0,0,1,0,0,-2.1,GO:0048934,peripheral nervous system neuron differentiation,M001,1,0
0,1,0,0,-2.5,0,GO:2000178,negative regulation of neural precursor cell proliferation,M010,1,0
1,0,0,-2.4,0,0,R-HSA-1489509,DAG and IP3 signaling,M100,1,0
0,0,1,0,0,-2.9,GO:0002833,positive regulation of response to biotic stimulus,M001,1,0
0,1,0,0,-2.1,0,GO:1903020,positive regulation of glycoprotein metabolic process,M010,1,0
1,0,0,-2.9,0,0,GO:0070482,response to oxygen levels,M100,1,0
0,1,0,0,-2.2,0,GO:0009896,positive regulation of catabolic process,M010,1,0
0,1,0,0,-2.9,0,GO:0010506,regulation of autophagy,M010,1,0
1,0,0,-3.1,0,0,GO:0001667,ameboidal-type cell migration,M100,1,0
1,0,0,-2.2,0,0,GO:0003203,endocardial cushion morphogenesis,M100,1,0
1,0,0,-2.5,0,0,WP4630,Measles virus infection,M100,1,0
0,0,1,0,0,-2.4,WP5092,Interactions of natural killer cells in pancreatic cancer,M001,1,0
0,0,1,0,0,-3.4,WP4564,Neural crest cell migration during development,M001,1,0
0,0,1,0,0,-2.2,GO:0043065,positive regulation of apoptotic process,M001,1,0
0,0,1,0,0,-5.2,GO:0021892,cerebral cortex GABAergic interneuron differentiation,M001,1,0
0,1,0,0,-4.2,0,R-HSA-202403,TCR signaling,M010,1,0
1,0,0,-2.7,0,0,R-HSA-168176,Toll Like Receptor 5 (TLR5) Cascade,M100,1,0
1,0,0,-2.2,0,0,R-HSA-452723,Transcriptional regulation of pluripotent stem cells,M100,1,0
1,0,0,-5.2,0,0,GO:2000629,negative regulation of miRNA metabolic process,M100,1,0
1,0,0,-2.4,0,0,GO:0010039,response to iron ion,M100,1,0
0,0,1,0,0,-2.1,GO:1901739,regulation of myoblast fusion,M001,1,0
0,0,1,0,0,-3,GO:0006909,phagocytosis,M001,1,0
1,0,0,-3.4,0,0,R-HSA-9823739,Formation of the anterior neural plate,M100,1,0
0,1,0,0,-3.4,0,GO:0034330,cell junction organization,M010,1,0
